Efficient, catalytic and scalable method to produce chlorine dioxide

ABSTRACT

Methods, kits, cartridges and compounds related to generating chlorine dioxide by exposing ClO 2   −  to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst are described.

This application claims the benefit of U.S. Provisional Application Nos. 61/376,052, filed Aug. 23, 2010, and 61/504,460, filed Jul. 5, 2011, both of which are incorporated herein by reference as if fully set forth.

This invention was made with government support under Grant # CHE-0616633 awarded by the National Science Foundation. The government has certain rights in this invention.

FIELD

The disclosure herein relates to the preparation of chlorine dioxide.

BACKGROUND

Chlorine dioxide (ClO₂) may be used in a variety of settings. It is an oxidizing agent that is employed in place of chlorine since it has superior antimicrobial properties and a reduced tendency to produce harmful organic chlorine by-products. Chlorine dioxide is used primarily (>95%) for bleaching of wood pulp, but is also used for pathogen decontamination, water treatment, bleaching of flour and disinfection of municipal drinking water. Its most common use in water treatment is as a pre-oxidant prior to chlorination of drinking water to destroy natural water impurities that produce trihalomethanes on exposure to free chlorine. Trihalomethanes are suspect carcinogenic disinfection byproducts associated with chlorination of naturally occurring organics in the raw water. Chlorine dioxide is also superior to chlorine when operating above pH 7, in the presence of ammonia and amines and/or for the control of biofilms in water distribution systems. Chlorine dioxide is used in many industrial water treatment applications, and as a biocide in cooling towers, water processing and food processing. Chlorine dioxide is less corrosive than chlorine and superior for the control of legionella bacteria.

Chlorine dioxide is also more effective as a disinfectant than chlorine in most circumstances against water borne pathogenic microbes such as viruses, bacteria and protozoa—including cysts of Giardia and the oocysts of Cryptosporidium.

Chlorine dioxide can also be used for air disinfection, and was the principal agent used for decontamination of buildings in the United States after the 2001 anthrax attacks. Recently, after the disaster of Hurricane Katrina in New Orleans, La. and the surrounding Gulf Coast, chlorine dioxide has been used to eradicate dangerous mold from houses inundated by water from massive flooding. Chlorine dioxide is used as an oxidant for phenol destruction in waste water streams, control of zebra and quagga mussels in water intakes and for odor control in the air scrubbers of animal byproduct (rendering plants). Stablilized chlorine dioxide can also be used in an oral rinse to treat oral disease and malodor.

The industrial preparation of chlorine dioxide is energy-intensive and fraught with health and safety issues. Furthermore, due to the instability of ClO₂ at high pressures, the gas is often generated where it is to be used. Large-scale production of ClO₂ may involve the use of such reagents as concentrated strong acids and/or externally-added oxidants (such as Cl₂, H₂O₂, or hypochlorite). Electrochemical methods can directly oxidize ClO₂ ⁻ to ClO₂ by a 1-electron process but require considerable input of electrical energy and may not be applicable in rural or underdeveloped areas of the world. An iron-catalyzed decomposition of ClO₂ ⁻ has been shown to afford ClO₂ (in part), but only under very acidic conditions. Since ClO₂ is often generated where it is to be used, these hazardous and/or costly methods must be implemented in facilities that are primarily engineered for other purposes.

SUMMARY

In an aspect, the invention relates to a method of generating chlorine dioxide. The method includes exposing ClO₂ ⁻ to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst.

In an aspect, the invention relates to a kit for generating chlorine dioxide. The kit includes at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst. The kit also includes instructions to combine the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst with ClO₂ ⁻.

In an aspect, the invention relates to a cartridge. The cartridge includes a housing and at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst in the housing. The cartridge is adapted to allow reactants to contact the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst.

In an aspect, the invention relates to a method of treating a substance. The method includes generating chlorine dioxide by exposing ClO₂ ⁻ to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst. The method also includes exposing the substance to the generated chlorine dioxide.

In an aspect, the invention relates to a composition. The composition includes a manganese porphyrazine compound having a structure of formula VI:

The “a” represents the oxidation state of the Mn and the oxidation state can be any of the possible oxidation states. Each of A₁, A₂, A₃, A₄, B₁, B₂, B₃, B₄, C₁, C₂, C₃, C₄, D₁, D₂, D₃, and D₄ are independently selected from N⁺—R_(n), C—H, C—X, and C—R_(n). When N⁺—R_(n) is selected, one or zero group in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, and D₄ is N⁺—R_(n). When N is selected, one or zero group in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, or D₄ is N. Each R_(n) is independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃. Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to the pyridoporphyrazine. n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl. R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃. Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃. Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃. Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃. Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃. Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O⁻, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH2)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y. Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂. W₁ is OH, or (O—(CH₂CH₂)_(m)OH). W₂ is OR₁₆ and R₁₆ is alkyl. Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—. L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description of the preferred embodiments of the present invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It is understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown. In the drawings:

FIG. 1A illustrates the structure of MnTDMImP. FIG. 1B illustrates the structure of MnTm-2,3-PyPz. Axial ligands may water and hydroxo under exemplary conditions used.

FIG. 2A illustrates Abs. v. wavelength, FIG. 2B illustrates a time resolved UV-vis spectra of ClO₂ generation.

FIGS. 3A-B illustrate cartridges that may be employed as portable chlorine dioxide generators.

FIG. 4 illustrates a GC-MS chromatogram of authentic DDA and the extract of a reaction of DDA reacted with ClO₂.

FIG. 5 illustrates a GC-MS chromatogram of DDA generated when MO was present during the turnover reaction of MnTDMImP and ClO₂.

FIGS. 6A-C illustrate (A and B) Spectroscopic changes showing rapid and efficient production of chlorine dioxide upon addition of the Mn catalyst to a sodium chlorite solution. (C) Kinetic traces showing the very fast reaction rate for Mn(III)TM-2,3-PyPz.

FIG. 7 illustrates the synthesis of two highly active catalysts, MnTm-2,3-PyPz and MnTm-3,4-PyPz. These can be any of the various regioisomers or a mixture thereof.

FIG. 8 illustrates the synthesis of Barrett and Hoffman's octacationic pyridium substituted tetraazapophyrin.

FIG. 9 illustrates the synthesis of (1-methyl-1H-imidazol-2-yl)acetonitrile.

FIG. 10 illustrates the manganese octakis[(bismethyl)imidazoliumyl]tetraazaprophyrin.

FIGS. 11A and B illustrate (A) Rapid appearance of ClO2 (359 nm) from the MnTDMImP-catalyzed decomposition of ClO2- (10 mM) at pH 6.8 with 0.1 mol % catalyst (445 nm) showing first 30 s of reaction, 1 scan/s; and (B) Similar reaction with MnTM23PyPz (9 mM sodium chlorite, 10 uM MnTM23PyPz, pH 4.7 100 mM acetate buffer, showing the first 30 s of reaction, 1 scan/s).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Certain terminology is used in the following description for convenience only and is not limiting. The words “a” and “one,” as used in the claims and in the corresponding portions of the specification, are defined as including one or more of the referenced item unless specifically stated otherwise. The phrase “at least one” followed by a list of two or more items, such as “A, B, or C,” means any individual one of A, B or C as well as any combination thereof.

An embodiment provides a method of generating chlorine dioxide from chlorite ion by exposing chlorite ion to at least one of a manganese porphyrin catalyst or manganese porphyrazine catalyst. The catalyst may be water soluble. A mixture of manganese porphyrin catalysts or manganese porphyrazine catalysts may be present in a method herein. A mixture may be two or more species of manganese porphyrin catalysts, two or more species of a manganese porphyrazine catalyst, or at least one species of manganese porphyrin catalyst plus at least one species of manganese porphyrazine catalyst. The species of manganese porphyrin catalyst may be selected from any manganese porphyrin compound herein. The species of manganese porphyrazine compound may be selected from any manganese porphyrazine compound herein. An embodiment provides a cartridge that may be implemented as a chlorine dioxide generator. An embodiment provides reagents for generating chlorine dioxide. An embodiment provides a new chemical process that allows the effective production of the disinfectant chlorine dioxide from common chlorite salts. An embodiment provides a method, apparatus and/or reagents to produce chlorine dioxide in rural areas that do not have modern facilities. An embodiment includes a new catalytic system that is able to produce gaseous chlorine dioxide on demand from easily transportable chlorite salts. A method herein includes contacting a chlorite salt in a solvent such as water containing a catalytic amount of a manganese porphyrin manganese porphyrazine catalyst. Chlorine dioxide is produced efficiently in minutes at ambient temperature and pressure under mild, non-acidic conditions. The catalyst may be free in solution. The catalyst can be immobilized on a solid support, which may be readily available clay. This may allow facile recovery of the catalyst and the construction of a flow system for continuous production of chlorine dioxide without electricity or other power sources. Embodiments include treating a substance with the ClO₂ generated by another embodiment herein. The substance may be but is not limited to a coolant, a liquid, water, air, a solid, or a surface. For example, coolant for use in or in a coolant tower may be exposed to ClO₂ generated by another embodiment herein.

In an embodiment, a unique feature of a manganese porphyrin catalyzed or manganese porphyrazine catalyzed method for the production of chlorine dioxide is that added oxidants such as hydrogen peroxide or chlorine are not necessary. Added reducing agents such as methanol or hydrogen peroxide or added acids such as sulfuric acid or hydrochloric acid are also unnecessary in an embodiment. This is due to the fact that the catalyst is able to utilize oxidation equivalents derived from the chlorite salt itself at a range of pH that is either neutral, mildly acidic or mildly basic. The net result for the reaction is a significant simplification of the process since complicated metering or potentially hazardous mixtures of hydrogen peroxide and either chlorate or chlorite salts are unnecessary.

Advances in chemical catalysis have numerous intrinsic advantages among the various strategies for mitigating pollution and workforce hazards in chemical practice. Methods herein provide an efficient, catalytic process for the generation of ClO₂ from chlorite ion (ClO₂ ⁻). A method herein may include a manganese porphyrin catalyst. A method herein may include a manganese porphyrazine catalyst. The catalyst may be the water-soluble manganese porphyrin tetrakis-5,10,15,20-(N,N-dimethylimidazolium) porphyrinatomanganese(III), MnTDMImP (FIG. 1A). The catalyst may be MnTM-2,3-PyPz (FIG. 1B). The reaction may proceed rapidly and efficiently under mild, ambient conditions.

Embodiments herein offer a potentially greener alternative to the other commonly employed routes of ClO₂ preparation. The reactions available can be carried out in an aqueous system at near-neutral pH under ambient pressure and temperature. In an embodiment, a method of generating ClO₂ and optionally of treating a substance with the generated ClO₂ includes MnTDMImP-catalyzed decomposition of ClO₂ ⁻ (10 mM) at pH 6.8 with 0.1 mol %. Under these conditions, ClO₂ may be formed within seconds, and the reaction may be complete within minutes. In an embodiment, a method of generating ClO₂ and optionally of treating a substance with the generated ClO₂ includes the catalyst MnTM23PyPz (9 mM sodium chlorite, 10 uM MnTM23PyPz, pH 4.7 in 100 mM acetate buffer). Other reaction conditions may be provided in a method herein.

A manganese porphyrin catalyst or a manganese porphyrazine catalyst may be present in a method, kit or cartridge herein at any concentration from 0.05% to 1% by weight chlorite where %=[(weight catalyst)/(weight chlorite)]×100. A manganese porphyrin catalyst or a manganese porphyrazine catalyst may be present at any concentration in a sub-range within 0.05% to 1% by weight chlorite. The lower value in the sub-range may be any value from 0.05% to 0.99% in 0.01% increments. The higher value in the sub-range may be any value from 0.01% greater than the lower value to any value up to and including 1% in 0.01% increments. A sub-range may be 0.1% to 0.5% by weight chlorite. When a mixture of manganese porphyrin catalysts or manganese porphyrazine catalyst is present the “weight catalyst” may be calculated as the combined weight of the catalysts in the mixture. Catalyst concentrations outside of these ranges may be provided in a method, kit or cartridge herein.

A manganese porphyrin catalyst or a manganese porphyrazine catalyst may be present in a method, kit or cartridge herein at any concentration from 1 to 500 micromolar. The concentration may be any one integer value selected from the range 1 to 500 micromolar. A manganese porphyrin catalyst or a manganese porphyrazine catalyst may be present at concentration in a sub-range within 1 to 500 micromolar. The lower value in the sub-range may be any value from 1 micromolar to 499 micromolar in 1 micromolar increments. The higher value in the sub-range may be any value from 1 micromolar greater than the lower value to any value up to and including 500 micromolar in 1 micromolar increments. A sub-range may be 5-50 micromolar. When a mixture of manganese porphyrin catalysts or manganese porphyrazine catalyst is present, the concentration may be calculated based on the total amount of catalyst present. Catalyst concentrations outside of these ranges may be provided in a method, kit or cartridge herein.

As described below, a manganese porphyrin catalyst or a manganese porphyrazine catalyst may be provided on a solid support. A manganese porphyrin catalyst or a manganese porphyrazine catalyst may be provided in a method, cartridge or kit herein at a concentration of 0.1% to 5% catalyst by weight solid support where %=[(weight catalyst)/(weight of the solid support)]×100. A manganese porphyrin catalyst or a manganese porphyrazine catalyst may be present at any concentration in a sub-range within 0.1% to 5% by weight solid support. The lower value in the sub-range may be any value from 0.1% to 5% in 0.1% increments. The higher value in the sub-range may be any value from 0.1% greater than the lower value to any value up to and including 5% in 0.1% increments. A sub-range may be 0.1% to 1% by weight solid support. When a mixture of manganese porphyrin catalysts or manganese porphyrazine catalyst is present the “weight catalyst” may be calculated as the combined weight of the catalysts in the mixture. Catalyst concentrations outside of these ranges may be provided in a method, kit or cartridge herein.

The chlorite concentration in a method, kit or cartridge herein may be at any concentration from 0.5 millimolar to 1 molar. The chlorite concentration may be any value in a sub-range from 0.5 millimolar to 1 molar. The lower value of the sub-range may be any value from 0.5 to 999 millimolar in 1 millimolar increments. The higher value in the sub-range may be any value from 1 millimolar greater than the lower value to 1 molar in 1 millimolar increments. A sub-range may be 1-500 millimolar. Chlorite concentrations outside of these ranges may be provided in a method, kit or cartridge herein.

A method herein may include reaction conditions at a pH of 1-14, or any value therein. The pH may be 2 to 8. The pH may be 4.5 to 7.2. The pH may be at a value in a range selected from any two integer values selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14. A kit or cartridge herein may include reagents or conditions such that a reaction utilizing the kit or cartridge has any of the above pH values. A method herein may be conducted at any temperature allowing the reaction to proceed. The temperature may be from the freezing point to the boiling point of the mixture. The temperature may be from 0° C. to 100° C. The temperature may be any integer value from 0° C. to 100° C. The temperature may be any value in a sub-range between any two integer values from 0° C. to 100° C.

Additives may be provided in a method, kit or cartridge herein. Additives that may be provided include but are not limited to acetate or phosphate buffer, and sodium chloride to maintain ionic strength. Other additives to buffer or provide ionic strength may also be provided. The acetate or phosphate buffer may be at any concentration from 10 millimolar to 500 millimolar, or at any value in a sub-range between any two integer values from 10 millimolar to 500 millimolar. The sodium chloride may be at any concentration from 10 millimolar to 600 millimolar, or at any value in a sub-range between any two integer values from 10 millimolar to 600 millimolar. Additive concentrations may be provide outside of these ranges.

A manganese porphyrin catalyzed or manganese porphyrazine method for the production of chlorine dioxide described here may also produce bromine if sodium or potassium bromide, or some similar bromide salt, is present as an additive. Bromide ion can intercept and react with both reactive chlorine species such as hypochlorite or chlorine dioxide and reactive manganese-oxo complexes derived from the catalyst to produce bromine. Bromine is similar in effectiveness to chlorine as a disinfectant and may have advantages in the presence of chlorine dioxide or if all of the chlorine dioxide is subsequently converted to bromine. Methods herein include providing bromide ion in addition to chlorite ion and at least one of a manganese porphyrin catalyst or manganese porphyrazine catalyst. A kit or cartridge herein may also be adapted to include bromide and be used to produce bromine. The bromide concentration in a method, kit or cartridge herein may be at any concentration from 0.5 millimolar to 2 molar. The bromide concentration may be any value in a sub-range from 0.5 millimolar to 2 molar. The lower value of the sub-range may be any value from 0.5 to 1999 millimolar in 1 millimolar increments. The higher value in the sub-range may be any value from 1 millimolar greater than the lower value to 2 molar in 1 millimolar increments. A sub-range may be 1 to 500 millimolar, or 1 to 1000 millimolar. Bromide concentrations outside of these ranges may be provided in a method, kit or cartridge herein.

A composition may be provided having any one or more catalyst herein and any one or more of the constituents above. The concentration of catalyst and the any one or more constituent above may be but are not limited to those listed above.

In addition, the use of a manganese porphyrin or porphyrazine as a catalyst may avoid the necessity of auxiliary oxidizers or acids, since the reaction is self-initiating. A method herein may include removing ClO₂ gas produced from a reaction herein. The ClO₂ may be removed from a reaction vessel; e.g., by using a simple apparatus. For example, gaseous ClO₂ may be removed from the reaction mixture by sparging with nitrogen, helium or air. The sparging tube and optionally a frit may be placed at the bottom of the reaction mixture and the ClO₂ may be trapped in cold water. The removed ClO₂ may be used to oxidize a substrate. The yield may be almost 60%. An efficiently-engineered generator could take full advantage of the oxidizing power of the ClO₂. A heterogeneous version of this process would adapt well to flow or cartridge systems for water purification and would facilitate removal and recycling of the catalyst. Embodiments provide such systems.

Porphyrin catalysts are discussed in U.S. application Ser. No. 12/311,639, which was a 35 USC 371 national phase application of PCT/US2007/021453 filed Oct. 5, 2007 and is incorporated herein by reference as if fully set forth. Porphyrin catalysts are also discussed in U.S. Pat. Nos. 6,448,239 and 6,969,707, which are incorporated herein by reference as if fully set forth. The embodiments described herein extend the knowledge of porphyrin catalysts and methods of use thereof. One or more of the porphyrin catalysts in U.S. application Ser. No. 12/311,639 or U.S. Pat. Nos. 6,448,239 and 6,969,707 may be utilized in an embodiment herein.

A manganese porphyrin catalyst for any embodiment herein may have a structure of formula I:

R₁, R₂, R₃ and R₄ may be independently selected from the group consisting of TM2PyP, TM4PyP, TDMImP, and TDMBImp, which have a structure of formulas II, III, IV and V, respectively:

Examples of R₅, R₆, R₇, R₈, R₉, and R₁₀ are provided below. R₁, R₂, R₃, and R₄ may be independently selected from any substituent such that the resulting porphyrin has catalytic activity for the production of chlorine dioxide from chlorite. R₅, R₆, R₇, R₈, R₉, and R₁₀ may be independently selected from any substituent such that the resulting porphyrin has catalytic activity for the production of chlorine dioxide from chlorite. Acronyms: TM2PyP, tetra-(N-methyl)-2-pyridyl porphyrin; TM4PyP, tetra(Nmethyl)-4-pyridyl porphyrin; TDMImP, tetra-(N,N-dimethyl)-imidazolium porphyrin; TDMBImP, tetra(N,N-dimethyl)-benzimidazolium porphyrin; The superscripted “a” represents oxidation state of the Mn. The oxidation state may be any possible oxidation state. The oxidation state may be II, III or IV in non-limiting examples; axial ligands are represented by L₁ and L₂. Both Ls may be absent, or the complexes may be either 5-coordinate with one L ligand or 6-coordinate with two L ligands. The complexes may have charge balancing counter anions. A non-limiting example of a charge balancing counter anion is chloride ion. Further non-limiting examples of charge balancing counter anions are provided below.

A manganes porphyrazine catalyst for any embodiment herein may have a structure of formula VI:

One or zero of A₁, B₁, C₁, and D₁ may be N⁺—R_(n), where the N⁺ occupies the position of A₁, B₁, C₁ or D₁. One of A₂, B₂, C₂, and D₁ may be N⁺—R_(n) where the N⁺ occupies the position of A₂, B₂, C₂, or D₂. One or zero of A₃, B₃, C₃, and D₃ may be N⁺—R_(n) where the N⁺ occupies the position of A₃, B₃, C₃, or D₃. One or zero of A₄, B₄, C₄, and D₄ may be N⁺—R_(n) where the N⁺ occupies the position of A₄, B₄, C₄, or D₄. One or zero of A₁, B₁, C₁, and D₁ may be N. One or zero of A₂, B₂, C₂, and D₂ may be N. One or zero of A₃, B₃, C₃ and D₃ may be N. One or zero of A₄, B₄, C₄, and D₄ may be N. Each of the remaining A_(i)-D_(i) may be independently selected from C—H, C—X, and C—R_(n) where i is 1, 2, 3, or 4 and the C occupies the position of A_(i), B_(i), C_(i) or D_(i). X is as defined below with respect to R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄. R_(n) may be any one of R11-R14 as described below. Each R_(n) may be independently selected from any substituents such that the resulting porphyrazine has catalytic activity for the production of chlorine dioxide from chlorite. The superscripted “a” represents the oxidation state of the Mn. The oxidation state may be any possible oxidation state. The oxidation state may be II, III, or IV in non-limiting examples. Axial ligands are represented by L₁ and L₂. Both L₁ and L₂ may be absent, or the complexes may be either 5-coordinate with one L ligand or 6-coordinate with two L ligands. The complexes may have charge balancing counter anions. A non-limiting example of a charge balancing counter anion is chloride ion. Further non-limiting examples of charge balancing counter anions are provided below.

An example where D1, D2, D3 and D4 are N⁺—R₁₁, N⁺—R₁₂, N+—R₁₃, and N⁺—R₁₄, respectively, is shown in formula VII:

A regioisomer or positional substituted compound based on formula VI may be provided as a porphyrazine catalyst herein. A mixture of regioisomers or positional substituted compounds may be provided as a porphyrazine catalyst herein. Non-limiting examples of regioisomers, mixtures thereof or mixtures of positional substituted compounds that may be provided as a phorphyrazine catalyst are shown below in formulas VIII through XIV.

Due to the method of synthesis, mixed isomers can be prepared by using a mixture of dicyanoolefins as starting materials and a mixture of alkylating agents R₁₁-LG, R₁₂-LG, R₁₃-LG, and R₁₄-LG with LG being a typical leaving group. Examples of leaving groups include but are not limited to iodide, triflate, bromide and tosylate. Formulas IX and X show two of four possible regioisomers.

Formulas XI and XII show two of four possible additional regioisomers.

Formulas XIII and XIV show two of four possible additional regioisomers.

Any possible regioisomer or combinations thereof of any of the above phorphyrazine compounds may be provided as a porphyrazine catalyst in embodiments herein.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; or —CH₂—Ar—X where Ar may be phenyl, biphenyl or naphthyl. For the phenyl case, X may be attached ortho- meta- or para to the —CH₂— attached to the pyridoporphyrazine. X is described below.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from H; (CH₂)_(n)—X where n is 1 to 10 and X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl. R₁₅ may be H, alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃. Z₁ may be CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃. Z₂ may be CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃ and Z₄ may be CH₂OCH₂CH₂X, or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃. Z₅ may be CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃ and Z₆ may be CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O⁺, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y. p may be 1 or 2. Y may be OH or (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂, where W₁ is OH, or (O—(CH₂CH₂)_(m)OH) and W₂ is OR₁₆, and R₁₆ is alkyl. m is 1 to 200. Y₂ may be —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—, where p is 1 or 2, and n is 1 to 10.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from H, (CH₂)_(m)Ar—X or (CH₂)_(m)Ar—Y, where Ar is substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl, m is 1 to 200, and X and Y are as defined above.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from (CH₂)_(n)—Y, where n is 1 to 10 and Y is as defined above.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R_(n), R₁₂, R₁₃, and R₁₄ may be independently selected from CH₂CONH—Y, CH₂COO—Y, or CH₂CO(CH₂)_(P)—Y, where p is 1 or 2 and Y is as defined above.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from (OCH₂CH₂)_(m)—Y, where Y is as defined above.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from (OCH₂CH₂)_(m)—X, where m is 1 to 200, and X is as defined above.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from Y₂—X, where X and Y₂ are as defined above.

Any one or more of R₅, R₆, R₇, R₈, R₉, and R₁₀, or R₁₁, R₁₂, R₁₃, and R₁₄ may be independently selected from —CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ or —CH₂CO₂CH₂CH₃.

In an embodiment, one of R₅, R₆, R₇, R₈, R₉, or R₁₀ is selected from one of the examples below other than H, and the remaining ones of R₅, R₆, R₇, R₈, R₉, or R₁₀ are H. In an embodiment, one of R₁₁, R₁₂, R₁₃ or R₁₄ is selected from one of the examples below other than H, and the remaining ones of R₁₁, R₁₂, R₁₃ or R₁₄ are H.

In some embodiments, a porphyrin or porphyrazine catalyst is provided in association with suitable ligands (L₁ and L₂) and/or charge neutralizing anions. L₁ and L₂ can be the same or different, and one or more may be absent. The structures above showing L₁ and L₂ thus include the possibility that L₁ and L₂ can be the same or different, and one or more may be absent. Ligands and charge neutralizing anions can be derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof. Ligands and charge neutralizing anions may be independently selected from the group consisting of halide, oxo, aquo, hydroxo, alcohol, phenol, dioxygen, peroxo, hydroperoxo, alkylperoxo, arylperoxo, ammonia, alkylamino, arylamino, heterocycloalkyl amino, heterocycloaryl, amino, amine oxides, hydrazine, alkyl hydrazine, aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate, isocyanate, isothiocyanate, alkyl nitrite, aryl nitrile, alkyl isonitrile, aryl isozutrile, nitrate, nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl sulfoxide, alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfuric acid, aryl sulfinic acid, alkyl thiol carboxylic acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid, aryl thiol thiocarboxylic acid, alkyl carboxylic acid, aryl carboxylic acid, urea, alkyl urea, aryl urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl thiourea, alkyl aryl thiourea, sulfate, sulfite, bisulfate, bisulfite, thiosulfate, thiosulfite, hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl phosphine sulfide, aryl phosphine sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl phosphinous acid, phosphate, thiophosphate, phosphite, pyrophosphite, triphosphate, hydrogen phosphate, dihydrogen phosphate, alkyl guanidino, aryl guanidino, alkyl aryl guanidino, alkyl carbamate, aryl carbamate, alkyl aryl carbamate, alkyl thiocarbamate, aryl thiocarbamate, alkyl aryl thiocarbamate, alkyl ditbiocarbamate, aryl dithiocarbamate, alkyl aryl dithiocarbamate, bicarbonate, carbonate* perchlorate, chlorate, chlorite, hypochlorite, perbromate, bromate, bromite, hypobromite, tetrahalomanganate, tetrafluoroborate, hexafluorophosphate, hexafluoroanitmonate, hypophosphite, iodate, periodate, metaborate, tetraaryl borate, tetra alkyl borate, tartrate, salicylate, succinate, citrate, ascorbate, saccharinate, amino acid, hydroxamic acid, thiotosylate, and anions of ion exchange resins, or systems. When the charge neutralizing complex has a net positive charge, then a negatively charged counter ion may be provided. When the charge neutralizing complex has net negative charge, a counter ion selected from alkaline and alkaline earth cations, organic cations, alkyl cations or alkylaryl ammonium cations may be provided. Ligands L₁ and L₂ may be independently selected from halide, oxo, aquo, hydroxo and alcohol. Anionic counterfoils may be halide ions. Halide ions include fluoro, chloro, bromo or iodo ions. Ligands and counterions may be the same or different. For example, a metallic complex may have one or two chloro axial ligands and 1, 2, 3, or 4 chloride ions as charge neutralizing anions.

Non-limiting examples of “alkyl” include a straight-chain or branched-chain alkyl radical containing from 1 to 22 carbon atoms, or from 1 to 18 carbon atoms, or from 1 to 12 carbon atoms. Further non-limiting examples of “alkyl” include include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl and eicosyl. Lower alkyl refers to a straight-chain or branched-chain alkyl radical containing from 1 to 6 carbon atoms.

Non-limiting examples of “aryl” include a phenyl or naphthyl radical. The pheny or napthyl radicacl may carry one or more substituents selected from alkyl, cycloalkyl, cycloalkenyl, aryl, heterocycle, alkoxyaryl, alkaryl, alkoxy, halogen, hydroxy, amine, cyano, nitro, alkylthio, phenoxy, ether, trifluoromethyl, phenyl, p-tolyl, 4-methoxy-phenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and 1-naphthyl, 2-naphthyl, or similar substituents.

Non-limiting examples of “aralkyl” include an alkyl or cycloalkyl radical in which one hydrogen atom is replaced by an aryl radical. One example is benzyl, 2-phenylethyl.

“Heterocyclic” means ring structures containing at least one other kind of atom, in addition to carbon, in the ring. The most common of the other kinds of atoms include nitrogen, oxygen and sulfur. Examples of heterocycles include, but are not limited to, pyrrolidinyl, piperidyl, imidazolidinyl, tetrahydrofuryl, tetrahydrothienyl, furyl, thienyl, pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrazinyl, indolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, benzoxadiazolyl, benzothiadiazolyl, triazolyl and tetrazolyl groups.

Non-limiting examples of “cycloalkyl” include a cycloalkyl radical containing from 3 to 10, or from 3 to 8, or from 3 to 6 carbon atoms. Further non-limiting examples of such cycloalkyl radicals include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and perhydronaphthyl.

The term “cycloalkenyl” means a cycloalkyl radical having one or more double bonds. Examples include, but are not limited to, cyclopentenyl, cyclohexenyl, cyclooctenyl, cyclopentadienyl, and cyclooctadienyl.

Embodiments also include any isomer of the any of the above porphyrin or porphyrazine catalysts or a method, kit or cartridge involving the same. Also included are tautomers of the compounds or a method, kit or cartridge involving the tautomers. Tautomers may include compounds wherein one or more of the various R groups are simple variations of the substituents as defined therein, or substituents which are a higher alkyl group than that indicated. In another example, anions having a charge other than 1 can be used instead of anions having a charge of 1. Examples of anions having a charge other than 1 include carbonate, phosphate, and hydrogen phosphate. Using anions having a charge other than 1 will result in a slight modification of the general formula for the compounds set forth above, but the skilled artisan will recognize the slight modification.

Embodiments herein provide an efficient, catalytic process for the generation of ClO₂ from chlorite ion (ClO₂ ⁻). In an embodiment, the method includes contacting a chlorine salt in a solvent containing a catalytic amount of a particular manganese porphyrin or N-alkylpyridinium porphyrazine catalysts. The solvent may be water. Chlorine dioxide is produced efficiently in minutes at ambient temperature and pressure under mild, non-acidic conditions. The catalyst may be immobilized on a readily available clay. This allows facile recovery of the catalyst and would allow the construction of a flow system for continuous production of chlorine dioxide without electricity or other power sources.

Referring to FIGS. 1A-B, MnTDMImP was previously found to be the most effective porhyrin catalyst. The rationale for the high activity is the strong electron withdrawing effect of the pendant imidazolium substituent since it modulates both the manganese redox potential and the pKa of water and hydroxide bond to the metal center. Very recent data has shown that the readily available manganese porphyrazine catalyst Mn(III)TM-2,3-PyPz (either as separated regiosomers or a mixture thereof and the corresponding 3,4-isomer) are even more potent catalysts than MnTDMImp, with forty-fold higher activity. See Table 1, below. Related pthalocyanines, as well as Mn(II) and Mn(IV) oxidation states may be provided in embodiments herein.

TABLE 1 MnTM-2,3-PyPz is 40-fold faster than MnTDMImP Compound pH k_(RDS) (M⁻¹ s⁻¹) MnTDMImP 4.7 1.36 × 10² MnTDMImP 6.8 5.62 × 10¹ MnTM-2,3-PyPz 4.5 5.29 × 10³

In any method, kit, cartridge or composition herein, the following may be provided. A chlorite source may provided in any suitable form. A chlorite source may be any chlorite salt. Non-limiting examples of chlorite salts that may be provided as a chlorite source are sodium chlorite, potassium chlorite, calcium chlorite and magnesium chlorite. A catalyst herein may be provided on a solid support. The solid support may be a clay. The solid support may be montmorillonite. The solid support may be but is not limited to silica, alumina, glass beads, functionalized polystyrene or organic polymers. The ClO₂ ⁻ may be adsorbed on a substance, which may be but is not limited to clay, silica, alumina or organic polymers.

A method herein includes generating chlorine dioxide by exposing ClO₂ ⁻ to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst. The manganese porphyrin catalyst may be any compound that catalyzes the reaction of ClO₂ ⁻ to ClO₂. The manganese porphyrin catalyst may but is not limited to any of the manganese porphyrin compounds described herein. The manganese poyphyrazine catalyst may be any compound that catalyzes the reaction of ClO₂ ⁻ to ClO₂. The manganese porphyrazine catalyst may but is not limited to any of the manganese porphyrazine compounds described herein. The method may include providing a chlorite source. The chorite source may be a chlorite salt. The chlorite source may be but is not limited to sodium chlorite, potassium chlorite, calcium chlorite or magnesium chlorite. The chlorite salt may be mixed with a solid filler. The chlorite source may be adsorbed on a substance. The substance may be but is not limited to clay, silica, alumina or organic polymers.

The at least one of the manganese porphyrin catalyst or a manganese porphyrazine catalyst is adsorbed on a solid support. The solid support may be but is not limited to one or more of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.

A method herein includes treating a substance with the ClO₂ generated by any other method herein, or by any reaction or use of any kit or cartridge herein. The substance may be but is not limited to water, air, a solid, a surface, cooling liquid, cooling liquid in a cooling tower, surfaces where biofilms may develop or have developed, food processing equipment, food products, and oral hygiene products.

An embodiment includes a cartridge system for producing chlorine dioxide from chlorite salts. The cartridge may be utilized in any manner apparent herein. The cartridge may be utilized as a portable chlorine dioxide generator, or a cartridge system for water purification with catalytic, in situ production of chlorine dioxide from chlorite salts. A cartridge type generator of chlorine dioxide using a fixed bed flow type reactor is described. Sodium chlorite, or other typical chlorite salts can be used either pure, mixed with a solid filler or adsorbed on a substance. The substance may be but is not limited to clay, silica, alumina, or organic polymers. A manganese porphyrin and/or manganese porphyrazine catalyst may also be adsorbed on a solid support. The solid support may be but is not limited to clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.

Referring to FIG. 3A, a cartridge 300 may include a housing 305, and a first compartment 320 including a chlorite salt. The chlorite salt may be but is not limited to sodium chlorite. The cartridge 300 may have a second compartment 330 having a manganese porphyrin catalyst and/or a manganese porphyrazine catalyst. Any manganese porphyrin or manganese porphyrazine catalyst may be provided in a cartridge, including any one or more of those listed herein. A fluid may be provided through an input 310 into the cartridge 300 and into the first compartment 320. The fluid may be water, or a solution made with water as the solvent. The chlorite salt may be dissolved in the fluid and then flow into the second compartment 330. The reaction to produce chlorine dioxide may occur in the cartridge 300. Fluid and/or chlorine dioxide may be provided through output 340. The cartridge may include additional constituents that could support the reaction to produce chlorine dioxide. For example, the cartridge could include buffer constituents.

As shown in FIG. 3A, the chlorite and catalyst may be in separate sections (as shown). Alternatively, the chlorite salt and catalyst could be mixed in a single section, or in a cartridge having no separate compartments. An interface; e.g., interface 345, between catalyst and chlorite salt may be included in a cartridge. The interface may be solid. The interface may be a complete barrier, or may have holes allowing retention of solid material. An interface could be made of a material that will allow mixing of the chlorite salt and catalyst upon a mechanical disruption. The mechanical disruption could be breaking of the interface. The mechanical disruption may be dissolution or other structural failure of the interface in the liquid. Holes in the interface may be provided in a configuration and/or size that does not allow passage of the chlorite salt or catalyst, but will allow passage of the fluid an solutes therein. The catalyst and chlorite compartments may be one unit, or two separate pieces that can be combined when in use. In the latter case, reuse of a catalyst bed may be more convenient. Alternatively, the cartridge may contain only the manganese porphyrin and/or manganese porphyrazine catalyst and the chlorite may be added to the fluid that is then allowed to flow over the catalyst bed.

The design of a cartridge may allow the production of either concentrated chlorine dioxide solutions to be later diluted into water that is to be treated or dilute (ppb-ppm) chlorine dioxide solutions that may be suitable for drinking or other such uses of water that has been decontaminated in this manner. An ion exchange cartridge may be inserted after the catalytic manganese flow reactor to reduce any effluent ClO_(x) salts. The cartridge system may also be fitted with a sparging tube or frit to remove pure ClO₂ from the reaction stream. The desired concentration of ClO₂, concentrated or dilute, can be obtained by varying the catalyst loading, chlorite salt concentration and flow rate of the chlorite solution over the catalyst bed.

Referring to FIG. 3B, a cartridge 350 is illustrated. The cartridge 350 inlcudes a housing 355, an input 360, an optional additional reagent input 365, an optional gas vent 370, and an output 375. Fluid may be deliverd into the cartridge 350 through the input 360. The cartridge 350 may include a manganese porphyrin and/or manganese porphyrazine catalyst within housing 355. Optionally, the cartridge 350 includes a compartment 380 including a manganese porphyrin and/or manganese porphyrazine catalyst. A chlorite solution may be provided as the fluid. Alternatively, a chlorite salt may be provided within the cartridge 350. For example, the chlorite salt may be provided in optional compartment 390. A catalyst in cartridge 350 may be provided absorbed on a solid support. A chlorite source in cartridge 350 may be provided absorbed on a substance and/or mixed with a filler.

An embodiment includes a cartridge having any configuration that allows containment of a catalyst and/or a chlorite salt, and then passage of a fluid through the cartridge. An embodiment includes a cartridge like that of U.S. Pat. No. 6,740,223, which is incorporated herein by reference as if fully set forth, but where the electrode elements are replaced by a catalyst and/or chlorite salt herein.

A cartridge may be made of any suitable material. The suitable material may include but is not limited to glass, wood, metal, plastic, polycarbonate, and polyallomer. Any method herein may be conducted by implemented any cartridge herein. In an embodiment, fluid is pumped through a cartridge including a chlorite source and including a manganese porphyrin and/or manganese porphyrazine catalyst. The fluid may be water. In an embodiment, a chlorite source is provided to a fluid, and the fluid plus chlorite source is pumped through a cartridge including a manganese porphyrin and/or manganese porphyrazine catalyst.

An embodiment includes a kit for producing chlorine dioxide. Embodiments include a kit for sanitizing a substance. A kit may include any catalyst herein. A kit may include a chlorite source herein. A kit may include instructions to contact the chlorite source with the catalyst. Any cartridge herein may be provided in a kit. The instructions may include details of the reaction conditions as provided herein, and/or instructions for using any cartridge herein. The kit may include instructions to conduct any one or more method herein.

An embodiment includes a compound selected from Mn^(III)TDMImP, Mn^(III)TM-2,3-PyPz, any isomeric form of Mn^(III)TM-2,3-PyPz, any manganese porphyrin catalyst herein, any isomeric form of any manganese porphyrin catalyst herein, any manganese porphyrazine catalyst herein, or any isomeric form of any manganese pophyrazine catalyst herein.

Additional embodiments include those formed by reading any dependent claim in the claim listing below as being dependent on any one or more preceding claim up to and including its base independent claim.

Further additional embodiments include those formed by supplementing any single embodiment herein or replacing an element in any single embodiment herein with one or more element from any one or more other embodiment herein.

EXAMPLES

The following non-limiting examples are provided to illustrate particular embodiments. The embodiments throughout may be supplemented with one or more detail from any one or more example below. Still further embodiments include a method utilizing any manganese porphyrin or manganese porphyrazine herein under any one experimental condition described in the following examples, or utilizing any manganese porphyrin or manganese porphyrazine herein under any one experimental condition that can be inferred based on those described in the following examples.

Example 1

Aliquots of ClO₂ ⁻ and Mn^(III)TDMImP stock solutions were added to 10 mL 100 mM buffer in a test tube with side arm and immediately sealed using a rubber stopper outfitted with a fritted sparging tube. The reaction mixture was sparged with He during the course of the reaction through another fritted bubbler into a second test tube containing 20-40 mL of aqueous 200 mM KI. The reaction was allowed to run for 20 minutes, at which point the trapping solution was transferred to an Erlenmeyer flask and titrated with 0.05 M sodium thiosulfate to a colorless endpoint (using a starch indicator). To the colorless solution, approximately 5 mL of concentrated H₂SO₄ was added to liberate more I₂. This solution was titrated again. The number of moles of ClO₂ transferred during the sparging was determined by dividing the number of moles of thiosulfate used in the second titration by 4. By subtracting the number of moles of ClO₂ calculated from the number of moles of thiosulfate used in the first titration and diving the total number by 2, the number of moles of Cl₂ transferred was determined.

Example 2 Heterogeneous Catalysis on Clay Support

Mn(III)TDMImP was supported on montmorillonite KSF by adding 1 mL of 2.5 mM MnTDMImP to a stirring, aqueous suspension of montmorillonite (˜200 mg/mL). Immediately the clay adsorbed the cationic porphyrin, and the supernatant had no color when the porphyrin-clay suspension was allowed to settle. Using the clay-bound MnTDMImP, catalyst-free solutions of ClO₂ could be prepared by stirring unbuffered solutions of NaClO₂ with aliquots of the MnTDMImP/clay slurry in an open reaction vial, followed by filtration through Celite/glass wool in a Pasteur pipet to remove the catalyst. Using 2 mg of the monified clay, a 5.5 mM solution of NaClO₂ produced 1 mM ClO₂ solution in 15 minutes (by UV-Vis analysis). With larger amounts of the MnTDMImP/clay (10-100 mg), the reaction was complete in less than 10 minutes, producing a catalyst-free 2.1 mM ClO₂ solution from a 9.5 mM solution of NaClO₂.

Example 3 Methyl Orange Test

In order to indirectly test for the generation of hypochlorite (ClO⁻) during turnover, methyl orange (MO, 4-dimethylaminoazobenzene-4′-sulfonic acid sodium salt) was added to the reaction of chlorite (ClO₂ ⁻) and MnTDMImP at pH 4.7. MO reacts with chlorinating oxidants such as ClO⁻, producing dichlorodimethylaniline (DDA). DDA can be extracted from the aqueous medium with heptane and observed by GC-MS (m/z=188).

As controls, the reactions of MO with chlorite ClO₂ ⁻, ClO⁻, and chlorine dioxide (ClO₂) were tested. ClO₂ ⁻ did not react at all with methyl orange at pH 4.7, whereas the other two oxidants quickly bleached the methyl orange chromophore (464 nm). ClO⁻ produced dichlorodimethylaniline (DDA), detectable by GC-MS. No DDA was ever observed in reactions of MO with ClO₂. Referring to FIG. 4, however, it was observed that ClO₂ quickly oxidized away authentic DDA to unknown products. The absence of DDA observable in reactions of MO and ClO₂ does not prove that DDA is not transiently produced.

Referring to FIG. 5, when MO was present in a solution of MnTDMImP prior to the addition of ClO₂ ⁻, a very small amount DDA (ca. 2 μmol) could be observed by GC-MS in heptane extracts of the reaction medium (1 mM ClO₂ ⁻, 1 mol % catalyst, 100 μmol MO). When MO was added to the catalytic reaction after 1 and 5 minutes of reaction, less DDA was observed. Because DDA is consumed by ClO₂ which is being generated during turnover, heptane extraction of the reaction mixture was done 1 minute after MO was added. Further, when MO was added to completed reactions of MnTDMImP/ClO₂ ⁻ (reaction time=10-30 min), no DDA was observed. This qualitative experiment therefore asserts that a species capable of chlorinating MO is produced during turnover. Given the above controls and our proposed mechanism, we assert that this chlorinating species is ClO⁻.

Example 4 Quantifying ClO₂ by Iodometry

At neutral pH, both ClO₂ and Cl₂ will react with iodide (I⁻) to produce iodine (I₂) (Reactions 1 and 2).

ClO₂+KI→KClO₂+½I₂  (1)

Cl₂+2KI→I₂+2KCl  (2)

In addition, in the presence of H₂SO₄, the KClO₂ produced in Reaction 1 above will further oxidize 2 I⁻ to I₂.

KClO₂+2H₂SO₄+4I⁻→KCl+2K₂SO₄+2I₂+2H₂O  (3)

By sparging the reaction vessel of ClO₂ ⁻ and MnTDMImP with helium into a concentrated I⁻ solution, I₂ was produced (Reactions 1 and 2), which was titrated to a colorless endpoint with sodium thiosulfate, after which the solution is acidified with H₂SO₄ (Reaction 3) and re-titrated to a second colorless endpoint. From these two titrations, the effective amounts of both ClO₂ and Cl₂ produced and isolated from the catalytic decomposition of NaClO₂ can be determined.

Example 5 Synthesis Synthesis and Characterization of Cationic Manganese and Iron Porphyrazines

Tetrapyridinoporphyrazine (PyPz) Water soluble cationic manganese tetrapyridinoporphyrazines were prepared using a modification of Wöhrle's method. Anhydrous manganese acetate was allowed to react with either 2,3- or 3,4-dicyanopyridine in a salt bath at 200° C. The green colored crude manganese tetrapyridinoporphyrazines (MnPyPpz) were precipitated with hexanes and then extracted with DMF to afford blue pure Mnpypz. Both Mn(2,3-pypz) and Mn(3,4-pypz) have four isomers each. Methylation was performed using dimethylsulphate in DMF yielding the cationic manganese tetrapyridinoporphyrazines as the methylsulfate salt (FIG. 7). The iron complexes have also been synthesized.

Aetato(2,3-pyridinoporphyrazinato)manganese(III) (Compound 1)

2,3-Dicyanopyridine (0.50 g, 3.9 mmol) and manganese acetate (0.17 g, 0.98 mmol) were dissolved in 1-chloronaphthalene (50 mL) and heated for 12 h at 200° C. Acetone (250 mL) was added to the cooled reaction mixture. The dark green product was filtered, washed with acetone and dried. Yield: 0.55 g (90%). Alternate method, 2,3-dicyanopyridine (0.50 g, 3.9 mmol) and manganese acetate (0.17 g, 0.98 mmol) were placed in a 4-mL vial and heated at 200° C. for 4 h. The deep blue product was washed with acetone and dried. Yield: 0.59 g (95%).

Acetato(N,N′,N″,N″′-tetramethyltetra-2,3pyridinoporphyrazinato)manganese(III) methylsulfate (Compound 2) Compound 1

(0.25 g, 0.40 mmol) was suspended in dry NMP (or DMF) (50 mL) and dimethyl sulfate (3.8 mL, 40 mmol) was added. The mixture was heated at 120° C. with stirring under argon for 12 h. Acetone (250 mL) was added to the cooled reaction mixture. The dark purple product was filtered, washed with acetone and dried. Yield: 0.385 g (85%).

Chloro(2,3-pyridinoporphyrazinato)iron(III) (Compound 3)

2,3-Dicyanopyridine (0.50 g, 3.9 mmol) and iron(II) chloride hydrate (0.20 g, 1.0 mmol) were placed in a 4-mL vial and heated at 200° C. for 4 h. The deep green product was washed with acetone and dried. Yield: 0.58 g (95%).

Chloro(N,N′,N″,N″′-tetramethyltetra-2,3 pyridinoporphyrazinato)iron(III) methylsulfate (Compound 4) Compound 3

(0.25 g, 0.41 mmol) was suspended in dry DMF (or NMP) (50 mL) and dimethyl sulfate (3.8 mL, 40 mmol) was added. The mixture was heated at 120° C. with stirring under argon for 12 h. Acetone (250 mL) was added to the cooled reaction mixture. The dark purple product was filtered, washed with acetone and dried. Yield: 0.400 g (88%).

PF₆ Salts of Compounds 2 and 4

The PF₆ salts of compound 2 and 4 were synthesized by anion exchange. Compound 2 (or 4) (0.20 mmol) was dissolved in H₂O (10 mL) and added to a solution of NH₄ PF₆ (0.75 g, 4.7 mmol) in H₂O (10 mL). The precipitate was filtered, washed with H₂O and dried. The yield was quantitative for both manganese and iron.

3,4 Isomers of Compounds 2 and 4

The 3,4 isomers of compounds 2 and 4 were synthesized by using 3,4-dicyanopyridine instead of 2,3-dicyanopyridine. The overall yield of the manganese isomer was lower at 55%. Moreover, this complex was very sensitive and decomposed quickly even at low pH. The overall yield of the iron 3,4-isomer was similar to the iron 2,3-isomer at 82%.

The compounds were tested as oxidation catalysts and promoters.

Oxidation of Bromide

Oxone (200 μM) was added to Mn(TM-2,3-PyPc) (20 μM), NaBr (10 mM) in acetate buffer (pH=4.9) in a cuvette. The UV-vis spectrum showed the presence of Br₃-. Phenol Red (50 μM) was added to the cuvette. The UV-vis spectrum indicated bromination of the phenol red to bromophenol blue. When H₂O₂ (2 mM) was used as the oxidant, bromophenol blue was also produced as indicated by the UV-vis spectroscopy.

Oxidation of Chloride

Oxone (200 μM) was added to Mn(TM-2,3-PyPc) (20 μM), NaCl (200 mM) in acetate buffer (pH=4.9) in a testtube. The tube was shaken for 15 s and then methyl orange (200 μM) was added to the testtube and the tube was shaken for 1 min. Hexanes was added to extract the organic soluble molecules and GC-MS indicated the presence of mono- and dichloroaniline.

Epoxidation of CBZ

Oxone (300 nmol) was added to Mn(TM-2,3-PyPc) (50 nmol), CBZ (200 mmol) in acetate buffer (pH=4.9) in a testtube. By HPLC analysis, CBZ oxide was produced.

Octakis[(bismethyl)imidazoliumyl]tetraazaprophyrin[H₂(Me₂-Im)₈TAP]⁸⁺

The synthesis of octakis[(bismethyl)imidazoliumyl]tetraazaprophyrin will be performed in a similiar fashion to the synthesis of Barrett and Hoffman's octacationic pyridium substituted tetraazaporphyrin (FIG. 8). Barrett and Hoffman first synthesized 2,3-bis(4-pyridyl-2,3-dicyanomaleonitrile from oxidative dimerization of 4-pyridylacetonitrile hydrochloride. Since no commercial sources of (1-methyl-1H-imidazol-2-yl)acetonitrile are available, this compound was prepared by a procedure by Reese (FIG. 9). 1-Methylimidazole was allowed to react with excess paraformaldehyde at 160° C. to yield (1-methylimidazol-2-yl)methanol. The methanol complex was then allowed to react with thionyl chloride at reflux to give 2-(chloromethyl)-1-methylimidazole hydrochloride. Sodium cyanide was then allowed to react with this chloro complex to yield 1-methylimidazol-2-yl-acetonitrile. With 1-methylimidazol-2-yl-acetonitrile synthesized, following Barrett and Hoffman's procedure, the manganese octakis[(bismethyl)imidazoliumyl]tetraazaprophyrin should be able to be synthesized (FIG. 10).

Example 6 Proposed Mechanism I

Referring to FIGS. 2A-2B, a time resolved UV-vis spectra of ClO₂ (359 nm) generation when 10 μM MnTDMImP (445 nm) is mixed with 1.9 mM NaClO2 (260 nm) at pH 4.7 (100 mM acetate buffer) and T=25° C. The reaction time shown is 240 s, scanning every 10 s. As shown, upon mixing freshly prepared sodium chlorite solutions with MnTDMImP, a large and immediate increase in the UV absorbance at 359 nm signals the formation of ClO₂. The appearance of ClO₂ occurred within seconds, concurrent with a complete decrease in the ClO₂ absorbance at 260 nm. The acid-catalyzed disproportionation of ClO₂ ⁻ is sluggish above pH 3-4 and was insignificant on the time-scales studied here. During the initial burst of reaction, ˜50 equiv of ClO₂ were quickly generated from 190 equiv of ClO₂ ⁻. O₂-evolution, as monitored using a Clark electrode, was insignificant (<2%) The only porphyrin species observed in solution during turnover was the starting Mn^(III) catalyst, as evidenced by the unshifted and undiminished Soret band at 445 nm. Significantly, the process also proceeded efficiently when the catalyst was adsorbed on montmorillonite clay.

The manganese porphyrin-catalyzed appearance of ClO₂ was observed from pH 4.7-6.8 over the temperature range 5-35° C. When ClO₂ ⁻ was mixed rapidly with MnTDMImP (0.5 mol %) the observed concentration of ClO₂ produced reached a plateau within two minutes (FIG. 2B). Initial turnover frequencies at 25° C. for 2 mM ClO₂ ⁻ and 10 μM catalyst were 1.00, 1.03, and 0.47 s⁻¹ at pH 4.7, 5.7, and 6.8, respectively, but these bulk values could be underestimates. The maximum amount of ClO₂ achieved was not temperature dependent.

The hypochlorite ion produced in the initial step would also be expected to oxidize Mn^(III)TDMImP as shown in Scheme 1. This stoichiometry predicts that five equiv of ClO₂ ⁻ would be dismutated to 4 equiv of ClO₂ and 1 equiv of Cl⁻ in this process. The observed unchanged oxidation state of the catalyst during turnover (FIG. 1) requires that any change in the Mn^(III) porphyrin oxidation state be slow relative to Mn^(III)-regenerating reactions. As ClO⁻ is a fast oxidant of Mn^(III), the oxidation of Mn^(III) by ClO₂ ⁻ may be the rate-determining step of the overall catalytic cycle. At neutral pH, the calculated reduction potentials for the oxoMn^(V)/Mn^(III) couple are lowest for TDMImP. Therefore, the imidazolium porphyrin should be oxidized most readily by ClO₂ ⁻, which is consistent with oxo-transfer from ClO₂ ⁻ being the RDS. At higher pH (where no ClO₂ generation was observed), ClO₂ ⁻ should be strong enough to oxidize Mn^(III) fully to Mn^(V) based on the predicted energetics of both species. At pH 8.0 the reaction of ClO₂ ⁻ and Mn^(III)TDMImP produced the O═Mn^(IV) porphyrin, characterized by its broadened and slightly blue-shifted Soret. Presumably, ClO₂ ⁻ oxidizes Mn^(III) to oxoMn^(V), which is quickly reduced by another ClO₂ ⁻ to oxoMn^(IV). The catalytic cycle in Scheme 1 would then stall at the Mn^(IV) oxidation state because the O═Mn^(IV) compound cannot efficiently oxidize ClO₂ ⁻ and return to the resting Mn^(III) state at this pH.

ClO₂ gas generated from the catalytic decomposition of ClO₂ ⁻ was removed via efficient sparging of a reaction vessel charged with pH 6.8 phosphate buffer, ClO₂ ⁻, and the catalyst. This effluent was bubbled through chilled, distilled water, which took on the characteristic color of dilute aqueous ClO₂ and could be confirmed by UV-Vis spectroscopy. The ClO₂ collected in this way was trapped and titrated with added iodide. Iodide is readily oxidized to I₂ by ClO₂, which could then be quantified by titrimetry. Using this procedure, 46.6 μmoles of ClO₂ were recovered from a 25° C. reaction of 98.4 μmoles of NaClO₂ with 10 μM MnTDMImP (reaction volume 10 mL) at pH 6.8 (60% yield, ˜500 turnovers). A small amount of iodide oxidation attributable to Cl₂ (3.7 μmol) was also observed.

The various reactions of ClO₂ ⁻ with metalloporphyrins reported to date are highly diverse in terms of intermediates and products. Accordingly, it is instructive to compare the reactivity of manganese porphyrin or phorphyrazine catalyst systems with that of other systems, both enzymatic and synthetic. Most notably, a water-soluble synthetic iron porphyrin that generates O₂ from ClO₂ ⁻ has been reported as a biomimic of the heme protein Cld. However, two other iron porphyrins were shown to dismutate ClO₂ ⁻ directly to chlorate (ClO₃ ⁻) and chloride (Cl⁻) with no observation of O₂. Collman and Brauman, who used ClO₂ ⁻ with a synthetic manganese porphyrin catalyst in oxidations of cyclohexane, also observed O₂ evolution in non-aqueous media. The heme-thiolate enzyme chloroperoxidase transiently generates ClO₂ from ClO₂ ⁻, ultimately producing a mixture of ClO₃ ⁻, Cl⁻, and O₂ via undetermined mechanisms. By contrast, a recent mechanistic study of ClO₂ ⁻ decomposition by horseradish peroxidase (HRP) has shown that ClO₂ ⁻ acts as both oxidant and reducing agent in a peroxidase cycle that generates ClO₂, but not ClO₃ ⁻. The present embodiments represents the only known generation of ClO₂ from a synthetic porphyrin system.

The proposed mechanism for ClO₂ ⁻ generation by manganese porphyrin or phorphyrazine is intriguing for its pronounced differences with a proposed mechanism for Cld and the iron porphyrin Cld-mimics. In Cld, the Cld-mimic Fe porphyrin, and MnTDMImP, ClO₂ ⁻ acts as a 2-electron oxo-transfer agent, producing either an oxoiron^(IV) porphyrin cation-radical or dioxoMn^(V) as well as an equivalent of ClO⁻. In the case of Cld and the iron mimic, the newly formed ClO⁻ presumably reacts with Compound I to form an oxygen-oxygen bond, leading to the release of O₂. However, ClO⁻ produced from the oxidation of Mn^(III)TDMImP by ClO₂ ⁻ appears not to react with the newly-formed dioxoMn^(V) species, but instead diffuses away to oxidize a second Mn^(III) site.

It appears that dioxoMn^(V) prefers an outer-sphere electron transfer from ClO₂ ⁻ over the O—O bond-forming inner sphere reaction with ClO⁻. This behavior might be influenced by electrostatics. As low as pH 5, the core of the catalyst exists as an anionic, trans-dioxo species [O═Mn^(V)═O]⁻. The work required to bring together two anions in an inner-sphere process could be far greater than that necessary for an outer sphere process (where ClO₂ ⁻ need only come qualitatively near the oxo species). Charge has been shown to be a powerful mediator of porphyrin reactivity, as in the example of olefin epoxidation by trans-dioxoMn^(V) porphyrins.

Example 7 Proposed Mechanism II

Referring to FIGS. 6A-C, the MnTm-2,3-PyPz catalyst was characterized. The UV-Vis spectra of MnTM2,3PyPz shows the characteristic porphyrazine Soret at 390 and Q-bands of intensity equal to the Soret. Normally these Q-bands are reported in the range 600-700 nm, but here we see 566 nm. The 800 nm absorbance is not found in Pz freebases, but similar absorbances have been reported for metallated Pz. Reactions of ClO₂ ⁻ with Mn(III)TM-2,3-PyPz were studied using UV-vis spectroscopy and rapid mixing kinetic techniques. Solutions of Mn(III)TDMImP and ClO₂ ⁻ were prepared in buffered siolutions and mixed 1:1. Final concentrations for reactions were obtained by dividing the initial concentrations by two. Thirty minutes elapsed between temperature setting and experiment to allow the cell holder and mixing accessory to equilibrate to the set temperature. Aliquots of ClO₂ ⁻ and Mn(III)TM-2,3-PyPz stock solutions were added to 10 mL 100 mM buffer in a test tube with side arm and immediately sealed using a rubber stopper outfitted with a fritted sparging tube. The reaction mixture was sparged with He during the course of the reaction through another fritted bubbler into a second test tube containing 20-40 mL of aqueous 200 mM KI for determination of total chlorine dioxide produced.

Alternatively, Mn(III)TH-2,3-PyPz was supported on montmorillonite KSF by adding 1 mL of 2.5 mM Mn(III)TH-2,3-PyPz to a stirring, aqueous suspension of montmorillonite (˜200 mg/mL). Immediately the clay adsorbed the cationic porphyrin, and the supernatant had no color when the porphyrin-clay suspension was allowed to settle. Using the clay-bound Mn(III)TH-2,3-PyPz, catalyst-free solutions of ClO₂ could be prepared by stirring unbuffered solutions of NaClO₂ with aliquots of the Mn(III)TH-2,3-PyPz/clay slurry in an open reaction vial, followed by filtration through Celite/glass wool in a Pasteur pipet to remove the catalyst. Using 2 mg of the monified clay, a 5.5 mM solution of NaClO₂ produced 1 mM ClO₂ solution in 15 minutes (by UV-Vis analysis). With larger amounts of the Mn(III)TH-2,3-PyPz/clay (10-100 mg), the reaction was complete in less than 10 minutes, producing a catalyst-free 2.1 mM ClO₂ solution from a 9.5 mM solution of NaClO₂.

The electron-deficient manganese(III) tetra-(N,N-dimethyl)imidazolium porphyrin (MnTDMImP), tetra-(N,N-dimethyl)benzimidazolium (MnTDMBImP) porphyrin and manganese(III) tetramethyl-2,3-pyridinium porphyrazine (MnTM23PyPz) were found to be the most efficient catalysts for the conversion of chlorite to chlorine dioxide at neutral pH and with mild conditions. The more typical manganese tetra-4-N-methylpyridiumporphyrin (Mn-4-TMPyP) was useful in the process, but less effective than Mn-4-TMPyP. Rates for the best catalysts were in the range of 0.24-32 TO/s with MnTM23PyPz showing the fastest turnover. The kinetics of reactions of the various ClO_(x) species (e.g. chlorite ion, hypochlorous acid and chlorine dioxide) with authentic oxomanganese(IV) and dioxomanganese(V) MnTDMImP intermediates were studied with stopped-flow spectroscopic methods, thus allowing independent confirmation of the individual steps in this catalysis. The proposed mechanism indicates a dual role for chlorite ion as both an oxidant and the substrate precursor to ClO₂. Rate-limiting oxidation of the manganese(III) catalyst by chlorite ion via oxygen atom transfer is proposed to afford a trans-dioxomanganese(V) intermediate. Both trans-dioxomanganese(V)TDMImP and oxoaqua-manganese(IV)TDMImP oxidize chlorite ion by 1-electron, generating the product chlorine dioxide with bimolecular rate constants of 6.30×10³ M⁻¹ s⁻¹ and 3.13×10³M⁻¹ s⁻¹, respectively, at pH 6.8. Chlorine dioxide was able to oxidize manganese(II)TDMImP to oxomanganese(IV) at a similar rate, establishing a redox steady-state equilibrium under turnover conditions. Another important oxygen transfer reaction controlling this process is the rapid, reversible oxygen atom transfer between dioxoMn(V)TDMImP and chloride ion. The measured equilibrium constant for this reaction (K_(eg)=2.2 at pH 5.1) afforded a value for the oxoMn(V)/Mn(III) redox couple under catalytic conditions (E′=1.35 V vs NHE). In subsequent processes, chlorine dioxide reacts with both oxomanganese(V) and oxomanganese(IV) TDMImP to afford chlorate ion. Kinetic simulations of the proposed mechanism using experimentally measured rate constants were in agreement with observed chlorine dioxide growth and decay curves, measured chlorate yields, and the oxoMn(IV)/Mn(III) redox potential (1.03 V vs NHE). This acid-free catalysis could form the basis for a new process to make ClO₂.

Catalytic Generation of ClO₂ from ClO₂ ⁻

The cationic, water-soluble manganese porphyrins (shown below) and a similar porphyrazine complex (also shown below) catalyzed the rapid production of chlorine dioxide from chlorite ion under mild conditions. The evolved ClO₂ could be monitored from the appearance of the characteristic chromophore at 359 nm (FIGS. 11A-B). During turnover, the visible spectra of the Mn^(III) catalysts remained largely unchanged, demonstrating the resistance of the catalyst to bleaching as well as providing mechanistic insight. The initial turnover rates for each of the studied catalysts are reported in 2. below. Extremely high activity (32 TO/s) was observed for the manganese(III) porphyrazine, MnTM23PyPz.

Acronyms: TM2PyP, tetra-(N-methyl)-2-pyridyl porphyrin; TM4PyP, tetra(N- methyl)-4-pyridyl porphyrin; TDMImP, tetra-(N,N-dimethyl)-imidazolium porphyrin; TDMBImP, tetra(N,N-dimethyl)-benzimidazolium porphyrin

Manganese porphyrins and porphyrazine studied as catalysts.

TABLE 2 initial turnover Catalyst frequency (s⁻¹) mol % cat. MnTM4PyP* 0.01 0.25 MnTM2PyP* 0.24 0.25 MnTDMImP* 0.40 0.25 MnTDMBImP* 0.48 0.50 MnTM23PyPz** 32.0 0.27 *pH 6.8 50 mM phosphate buffer, T = 25° C., 2.0 mM NaClO₂ **pH 4.5 50 mM acetate buffer, T = 25° C., 1.8 mM NaClO₂

The appearance of ClO₂ using MnTDMImP was studied in 100 mM acetate buffer (pH 4.7 and 5.7) and 100 mM phosphate buffer (pH 6.8). Initial turnover frequencies observed under these conditions at 25° C. for 2 mM ClO₂ ⁻ and 10 μM Mn^(III)TDMImP were 1.00, 1.03, and 0.42 at pH 4.7, 5.7, and 6.8, respectively. However, the turnover frequency was influenced more by buffer composition than by pH. Increasing buffer concentration and ionic strength (with added sodium perchlorate) was found to inhibit the MnTDMImP-catalyzed reaction by a factor of 5 in the range 5 mM-100 mM while at a constant buffer concentration, the turnover frequency did not change from pH 5.9 to 7.01.

When ClO₂ ⁻ was rapidly mixed with Mn^(III)TDMImP at 25° C., the spectroscopically-observed concentration of ClO₂ produced rose quickly and reached a plateau within 3 min. The product ClO₂ absorbance subsequently decayed in a slower process over the course of about 15 min. The maximum ClO₂ concentration was not affected by temperature (2.0 mM ClO₂, 10 μM MnIIITDMImP, 100 mM pH 6.8 phosphate buffer), although the reaction rate increased markedly from 5 to 35° C.

Reduction of oxoMn^(V) and oxoMn^(IV)TDMImP by ClO₂ ⁻

The reactions of both oxoMn^(V)TDMImP and oxoMn^(IV)TDMImP with ClO₂ ⁻ were studied by double-mixing, stopped-flow spectroscopy. In the first push, authentic oxoMn^(V) or oxoMn^(IV) was generated by mixing Mn^(III)TDMImP with 1 equiv of oxone or tBuOOH, respectively, in 10 mM pH 8.0 phosphate buffer. In the second push, oxoMn^(V) or oxoMn^(V) was mixed with an excess of ClO₂ ⁻ in 100 mM pH 4.7 acetate or pH 6.8 phosphate buffer. This “pH jump” experiment permitted observation of the reaction between each of the high-valent manganese species with ClO₂ ⁻ at lower pH values.

The decay of oxoMn^(V) (as measured by the characteristic Soret absorbance at 425 nm) was pH-dependant and followed pseudo-first order kinetics when mixed with an excess of ClO₂ ⁻. This decay was fit to a modeled exponential decay curve in order to obtain the observed pseudo-first order rate constant (k_(obs)), which was plotted as a function of [ClO₂ ⁻]. The apparent second-order rate constants (k_(app)) calculated from the slope of k_(obs) vs. [ClO₂ ⁻] are 6.8×10⁵ and 6.3×10³ M⁻¹ s⁻¹ at pH 4.7 and 6.8, respectively.

At pH 4.7, the 1-electron reduction of oxoMn^(V) by ClO₂ ⁻ was fast and allowed the direct observation of a reduced oxoMn^(IV)TDMImP catalyst with a single isosbestic point between a Soret bands at 437 nm (5 μM oxoMnVTDMImP and 125 μM ClO2- in 100 mM pH 4.7 acetate buffer over 0.3 s). By contrast, at pH 6.8 the reaction of oxoMn^(V) with ClO₂ ⁻ afforded Mn^(III) (10 μM oxoMnVTDMImP and 1.0 mM ClO2- in 100 mM pH 6.8 phosphate buffer over 3 s). The presence of two time-separated isosbestic points (436 nm and 432 nm) during this reaction demonstrated the intermediacy of oxoMn^(IV) in the reaction between oxoMn^(V) and ClO₂ ⁻. Under these conditions, the apparent second-order rate constant k_(app) was determined by first obtaining a pseudo-first order rate constant (k_(obs)) during the first phase of the reaction (where only the 436 nm isosbestic was observed).

The reaction between oxoMn^(IV) and an excess of ClO₂ ⁻ was similarly found to result in a pseudo-first order decay of oxoMn^(IV) to Mn^(III) (as measured by the characteristic Soret absorbance of oxoMn^(IV) at 422 nm) at pH 4.7 and 6.8 (10 μM oxoMnIVTDMImP and 1.0 M ClO₂- in 100 mM pH 4.7 acetate buffer over 3 s and 10 μM oxoMnIVTDMImP and 1.0 M ClO₂- in 100 mM pH 6.8 phosphate buffer over 1.5 s). A single isosbestic point was observed at 433 nm between the Soret bands of oxoMn^(IV) and Mn^(III). The apparent second-order rate constants measured for the reduction of oxoMn^(IV) by ClO₂ are 6.0×10³ and 3.1×10³M⁻¹ s⁻¹ at pH 4.7 and 6.8, respectively.

Measurement of K_(app) for Oxo-Transfer Between HOCl and Mn^(III)

The reaction between hypochlorous acid (HOCl) and Mn^(III)TDMImP was studied by single-mixing stopped-flow spectrometry. At pH 6.8, the reaction resulted in complete formation of oxoMn^(V) in <100 ms (Mn^(III)TDMImP with HOCl at pH 6.8, 5.1, or 4.7; buffer conditions—pH 6.8, 100 mM phosphate buffer; pH 4.7 and 5.1, 100 mM acetate buffer; reaction conditions—(a) 10 μM MnIII, 5 equiv HOCl; (b) 5 μM Mn^(III), 20 equiv HOCl; (c) 5 μM Mn^(III), 50 equiv HOCl). An apparent second-order rate constant for the reaction was determined by measuring k_(obs) of oxoMn^(V) appearance (425 nm) as a function of [HOCl]. The calculated rate constant (k₄) at pH 6.8 was 1.7×10⁶ M⁻¹ s⁻¹. An initial-rate analysis of oxoMn^(V) formation gave a slower rate constant of 1.47×10⁵ M⁻¹ s⁻¹.

At pH 4.7, complete formation of oxoMn^(V) could not be elicited with even a 50-fold excess of HOCl. Nevertheless, the apparent second-order rate constant (k₄=6.6×10⁴ M⁻¹ s⁻¹) under these conditions was calculated from a plot of k_(obs) for the decrease in Mn^(III) absorbance (444 nm) versus [HOCl]. A similar analysis using the method of initial rates provided a lower calculated k₄=4.22×10³ M⁻¹ s⁻¹. After a quick reaction time (<0.1 s at pH 4.7), the concentrations of Mn^(III) and oxoMn^(V) reached an apparent steady-state equilibrium. This steady-state observation can be better demonstrated at slightly less-acidic conditions of pH 5.1.

Reaction of ClO₂ with Mn^(III)TDMImP

In order to account for the observed decay of ClO₂ (FIG. 3), the reaction of ClO₂ with Mn^(III)TDMImP was investigated. The ClO₂ absorbance at 360 nm quickly disappeared in the presence of Mn^(III)TDMImP at pH 6.8, but not pH 4.7 (Initial [ClO₂] was 0.53 mM at pH 4.7 and 0.59 mM at pH 6.8). In both cases, the only porphyrin oxidation state observed in solution was Mn^(III).

Electron Transfer Between oxoMn^(IV), oxoMn^(V) and ClO₂

Stopped-flow techniques were again used to observe how high-valent species oxoMn^(V)TDMImP and oxoMn^(IV)TDMImP react with ClO₂. Both oxoMn^(V) and oxoMn^(IV) reacted with ClO₂ via 1-electron transfers. Although oxoMn^(IV) did not build up in the reaction of oxoMn^(V) with ClO₂, the observation of two, time-separated isosbestic points indicates the intermediacy of oxoMn^(IV) in the reaction. The product of 1-electron oxidation of ClO₂ is formally a chlorine(V) species, presumably chlorate (ClO₃ ⁻). The apparent second-order rate constants (k_(app)) for the reduction of oxoMn^(V) by ClO₂ were 1.6×10⁴ M⁻¹ s⁻¹ and 2.2×10⁴ M⁻¹ s⁻¹ at pH 6.8 and 4.7, respectively. Calculated k_(app) for the reduction of oxoMn^(IV) by ClO₂ are 1.2×10⁴ M⁻¹ s⁻¹ and 7.9×10³ M⁻¹ s⁻¹ at pH 6.8 and 4.7, respectively.

ClO₃ ⁻ Determination by HPLC

The observation that ClO₂ itself acted as a 1-electron reductant of oxoMn^(IV)TDMImP and oxoMn^(V)TDMImP suggests that some chlorine(V) species, presumably ClO₃ ⁻, was produced. An indirect UV-detection HPLC method was therefore employed to confirm and quantify the presence of ClO₃ ⁻ in reaction mixtures of either ClO₂ ⁻ or ClO₂ with Mn^(III)TDMImP (Table 3). Buffer, catalyst, ClO₂ ⁻, and ClO₂ stock solutions were free of ClO₃ ⁻ prior to reaction. A measured amount of either ClO₂ ⁻ or ClO₂ was added to solutions of MnTDMImP and stirred for ca. 1 h before being analyzed. Because the excess buffer anions co-eluted with chloride anion, the quantification of chloride produced by the catalytic decomposition of ClO₂ ⁻ could not be accomplished.

TABLE 3 Added substrate [ClO₃ ⁻]_(obsd) (mM) [ClO₃ ⁻]_(pred) (mM) 1 mM ClO₂ 0.7 0.8 1 mM ClO₂ ⁻ 0.6 0.7 2 mM ClO₂ ⁻ 1.7 1.4 Table 3 shows the measured concentrations of ClO₃ ⁻ produced ([ClO₃ ⁻]_(obsd)) from the reaction of 10 μM Mn^(III)TDMImP with a given amount of substrate (ClO₂ or ClO₂ ⁻) at pH 6.8. Also shown are the ClO₃ ⁻ concentrations predicted ([ClO₃ ⁻]_(pred)) by a kinetic model of the proposed mechanism (vida infra) given the same substrate/catalyst starting conditions.

Scheme 1, below, was proposed for the reaction mechanism.

The key initiating step in this catalytic cycle was suggested to be oxygen atom transfer from chlorite to the Mn^(III) catalyst to form trans-dioxoMn^(V)TDMImP. The thermodynamic driving force for oxo-transfer from chlorite ion is only slightly less than that of hypobromite ion (BrO⁻) (ΔΔG°=+16.7 kJ mol⁻¹). Hypobromite is a very facile oxo-transfer agent in its reaction with Mn^(III) porphyrins, with a rate constant for oxo-transfer from HOBr to Mn^(III)TDMImP ˜10⁵ M⁻¹ s⁻¹ at neutral pH. For the reaction with chlorite ion, the fact that the Mn^(III) oxidation state of the catalyst persisted during turnover requires that any change in the porphyrin oxidation state from Mn^(III) be slow relative to Mn^(III)-forming reactions. Therefore, it was concluded that the oxidation of Mn^(III) by ClO₂ ⁻ must be the rate-determining step of the overall cycle. Accordingly, a slower 2-electron oxidation of Mn^(III) by ClO₂ ⁻, generating HOClO and trans-dioxoMn^(V) is consistent with these observations. Interestingly, the pH-independence of the turnover rate implies that the oxygen transfer step to afford the Mn^(V) species is pH-independent and occurs at about the same rate as the analogous heterolysis of HOO—Mn^(III)TDMImP, which also affords Mn^(V).

The evolved ClO₂ can be efficiently removed from the reaction vessel via simple sparging or air stripping during turnover. Further, the catalysts are active on a solid support, suggesting their use in a flow system, a cartridge or a trickle-bed reactor. Methods for greatly enhancing the rate of ClO₂-generation and the reduction of impurities such as chlorine may be achieved by ligand tuning, or by using externally-added oxidants to overcome the relatively slow, chlorite-initiated oxo-transfer step.

Experimental

Reagents

Sodium chloride, sodium chlorate, t-butyl hydroperoxide (70% aqueous solution), and Oxone were purchased from Aldrich and used as received. Sodium chlorite was obtained from Aldrich as >80% technical grade and recrystallized twice from ethanol/water (>95% final). All oxidant stock solutions were prepared fresh daily and standardized by iodometeric titration before use. Dilute (0.5-10.0 mM) chlorite solutions were standardized spectrophotometrically (ε₂₆₀ nm=154 cm⁻¹ M⁻¹). Buffers were prepared fresh each day using either acetic acid/sodium acetate (pH=4.7, 5.7) or potassium phosphate (monobasic)/potassium phosphate (dibasic) (pH=6.8, 8.0) and pH-adjusting no more than 0.1 units using perchloric acid or sodium hydroxide. ClO₂ was prepared from ClO₂ ⁻ using a previously reported procedure. Briefly, a 2.5% w/w solution of NaClO2 was acidified with sulfuric acid under an argon flow in the dark. The evolved gas was carried by the argon flow through a gas scrubbing tower containing a 2.5% w/w solution of NaClO2 and bubbled through deionized water in a chilled amber bottle. Aliquots of the resulting solution were frozen at −30° C. for prolonged storage. The concentration of ClO₂ was checked immediately prior to use (ε₃₅₉ nm=1230 cm⁻¹ M⁻¹). Leftover ClO₂ from all experiments was neutralized with sodium iodide before being disposed of in general waste. Mn^(III)TDMImP was synthesized as the chloride salt using reported procedures. MnTM2PyP and MnTM4PyP were purchased from Mid Century and purified by double precipitation. MnTM23PyPz was prepared following the method of Wohrle. Briefly, manganese diacetate (170 mg) and pyridine-2,3-dicarbonitrile (500 mg) were heated in an unsealed reaction tube to 200° C. with mechanical stirring for 4 h. The deep blue solid product (a mixture of isomers) was washed with acetone, isolated by filtration, suspended in 50 mL DMF, and tetra-methylated using excess dimethyl sulfate at 120° C. for 12 h. Product was precipitated with acetone and purified by double precipitation.

Instrumentation

UV-Vis spectroscopic measurements were taken using a Hewlett-Packard 8453 diode array spectrophotometer equipped with a temperature-controlled cell housing, VWR 1140 thermostat bath and a Hi-Tech SFA Rapid Kinetics Accessory. Stopped-flow experiments for fast reactions were carried out using a Hi-Tech SF-61 double-mixing instrument with a 1 cm path length equipped with an ISOTEMP 1016 S thermostat bath. Ion chromatography was accomplished with an HPLC system consisting of a Waters 600 controller, Hamilton PRP X-100 column, and Waters 996 photodiode array detector.

Stopped-Flow Experiments

Reactions of ClO₂ ⁻ with Mn^(III) porphyrins were studied using traditional UV-vis and rapid mixing techniques. Solutions of catalyst and ClO₂ ⁻ were prepared in buffered solutions and mixed 1:1. All rate calculations were based on final concentrations resulting from this dilution. The oxidations of ClO₂ ⁻ and ClO₂ by oxoMn^(V)TDMImP and oxoMn^(IV)TDMImP were studied in double mixing mode using diode array detection. Solutions of Mn^(III)TDMImP and oxidant (oxone, tBuOOH) were prepared in weak pH=8.0 phosphate buffer (10 mM) and mixed 1:1 in a first push. After a short aging time to ensure complete conversion to the high-valent species (2-150 s, fine tuned for each experiment), the porphyrin solution was mixed 1:1 with the substrate (ClO₂ ⁻ or ClO₂) prepared in a higher strength buffer (100 mM) at the pH to be studied (4.7 or 6.8). All concentrations used in subsequent rate calculations accounted for the 4-fold and two-fold dilutions inherent to the double-mixing technique. Each reaction was run in duplicate or triplicate at T=25° C. Averaging of the runs and analysis of the data was accomplished using the KinetAsyst 3 software package. Kinetic simulations of the overall mechanism were performed with the Berkeley-Madonna software package.

Ion Chromatography Experiments

Aliquots of ClO₂ ⁻ or ClO₂ solutions were added to buffered solutions of Mn^(III)TDMImP under mechanical stirring at ambient temperatures. ClO₃ ⁻ was quantified using an indirect ion chromatography method. In brief, an aqueous solution of 4-aminosalicylic acid (4 mM) was pH adjusted to pH=6.0 and employed as the mobile phase. Reaction samples were injected directly without any modification. The eluent was monitored at 320 nm, and a decrease in absorbance was observed as anions were eluted. Concentration of analyte was calculated directly from total area of the peak using a concentration curve prepared daily using prepared standards.

REFERENCES

-   [1] Greenwood, Norman N.; Earnshaw, A. (1997), Chemistry of the     Elements (2nd ed.), Oxford: Butterworth-Heinemann, pp. 844-849, ISBN     0080379419 -   [2] Brockway L O (March 1933). “The Three-Electron Bond in Chlorine     Dioxide”. Proc. Natl. Acad. Sci. U.S.A. 19 (3): 303-7. PMID     16577512. -   [3] Pauling, Linus (1988). General chemistry. Mineola, N.Y.: Dover     Publications, Inc. ISBN 0-486-65622-5. -   [4] Flesch, R.; Plenge, J.; Riihl, E. (2006). “Core-level excitation     and fragmentation of chlorine dioxide”. International Journal of     Mass Spectrometry 249-250: 68-76. doi:10.1016/j.ijms.2005.12.046.     edit -   [5] Derby, R. I.; Hutchinson, W. S. “Chlorine(IV) Oxide” Inorganic     Syntheses, 1953, IV, 152-158. -   [6] Vogt, H.; Balej, J.; Bennett, J. E.; Wintzer, P.; Sheikh, S. A.;     Gallone, P.; Vasudevan, S.; Pelin, K. (2010). “Chlorine Oxides and     Chlorine Oxygen Acids”. Ullmann's Encyclopedia of Industrial     Chemistry. Wiley-VCH Verlag GmbH & Co. KGaA.     doi:10.1002/14356007.a06 483.pub2. edit -   [7] White, George W.; Geo Clifford White (1999). The handbook of     chlorination and alternative disinfectants (4th ed.). New York: John     Wiley. ISBN 0-471-29207-9. -   [8] Thomas Wilson Swaddle (1997). Inorganic chemistry: an industrial     and environmental perspective. Academic Press. pp. 198-199. ISBN     0126785503. -   [9] EPA Guidance Manual, chapter 4: Chlorine dioxide, US     Environmental Protection Agency,     http://www.epa.gov/OGWDW/mdbp/pdf/alter/chapt_(—)4.pdf, retrieved     2009-11-27 -   [10] Seymour Stanton Block (2001). Disinfection, sterilization, and     preservation (5th ed.). Lippincott Williams Wilkins. p. 215. ISBN     0683307401. -   [11] Sorlini, S.; Collivignarelli, C. (2005). “Trihalomethane     formation during chemical oxidation with chlorine, chlorine dioxide     and ozone of ten Italian natural waters”. Desalination 176 (1-3):     103-111. doi:10.1016/j.desa1.2004.10.022. -   [12] Li J.; Yu Z.; Gao M. (1996). “A pilot study on trihalomethane     formation in water treated by chlorine dioxide (translated from     Chinese)”. Zhonghua Yu Fang Yi Xue Za Zhi (Chinese journal of     preventive medicine) 30 (1): 10-13. PMID 8758861. -   [13] C. J. Volk; R. Hofmann; C. Chauret; G. A. Gagnon; G.     Ranger; R. C. Andrews (2002). “Implementation of chlorine dioxide     disinfection: Effects of the treatment change on drinking water     quality in a full-scale distribution system”. J. Environ. Eng. Sci.     1: 323-330. doi:10.1139/SO₂-026.     http://pubs.nrc-cnrc.gc.ca/rp/rppdf/s02-026.pdf. Retrieved     2009-11-27. -   [14] M. A. Pereira; L. H. Lin; J. M. Lippitt; S. L. Herren (1982).     “Trihalomethanes as initiators and promoters of carcinogenesis”.     Environ Health Perspect 46: 151-156. PMID 7151756. -   [15] Andrews, L.; Key, A.; Martin, R.; Grodner, R.; Park, D. (2002).     “Chlorine dioxide wash of shrimp and crawfish an alternative to     aqueous chlorine”. Food Microbiology 19 (4): 261-267.     doi:10.1006/fmic.2002.0493. edit -   [16] Zhe Zhang; Carole McCann; Janet E. Stout; Steve Piesczynski;     Robert Hawks; Radisav Vidic; Victor L. Yu (2007). “Safety and     Efficacy of Chlorine Dioxide for Legionella control in a Hospital     Water System”. Infection Control and Hospital Epidemiology 28 (8).     http://www.legionella.org/ZhangICHE07.pdf. Retrieved 2009-11-27. -   [17] Ogata N, Shibata T (January 2008). “Protective effect of     low-concentration chlorine dioxide gas against influenza A virus     infection”. J. Gen. Virol. 89 (Pt 1): 60-7.     doi:10.1099/vir.0.83393-0. PMID 18089729.     http://vir.sgmjournals.org/cgi/content/abstract/89/1/60?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&authorl=ogata+n&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=releva     nce&resourcetype=HWCIT. -   [18] Zhang, Y. L.; Zheng, S. Y.; Zhi, Q. (2007). “Air Disinfection     with Chlorine Dioxide in Saps”. Journal of Environment and Health 24     (4): 245-246.     http://www.csa.com/partners/viewrecord.php?requester=gs&collection=TRD&recid=07519213EN. -   [19] “Anthrax spore decontamination using chlorine dioxide”. United     States Environmental Protection Agency. 2007.     http://www.epa.gov/opp00001/factsheets/chemicals/chlorinedioxidefactsheet.htm.     Retrieved 2009-11-27. -   [20] Sy, Kaye V.; McWatters, Kay H.; Beuchat, Larry R. (2005).     “Efficacy of Gaseous Chlorine Dioxide as a Sanitizer for Killing     Salmonella, Yeasts, and Molds on Blueberries, Strawberries, and     Raspberries”. Journal of Food Protection (International Association     for Food Protection) 68 (6): 1165-1175. PMID 15954703.     http://www.ingentaconnect.com/content/iafp/jfp/2005/00000068/00000006/art00007. -   [21] Frascella J.; Gilbert R. D.; Fernandez P.; Hendler J. (2000).     “Efficacy of a chlorine dioxide-containing mouthrinse in oral     malodor”. Compend Contin Educ Dent 21 (3): 241-248. PMID 11199703. -   [22] Weitner, T.; Budimir, A.; Kos, I.; Batinic-Haberle, I.;     Birus, M. J. Chem. Soc., Dalton Trans. 2010,39, 11568-11576. -   [23] Budimir, A.; Smuc, T.; Weitner, T.; Batinic-Haberle, I.;     Birus, M. J. Coord. Chem. 2010, 63, 2750-2765. -   [24] Batanic-Haberle, I.; Benov, L.; Spasojevic, I.;     Fridovich, I. J. Biol. Chem. 1998, 273, 24521-24528. “The Ortho     Effect Makes Manganese (III) Meso-Tetrakis-(N-Methylpyridinium-2-yl)     Porphyrin a Powerful and Potentially Useful Superoxide Dismutase     Mimic.” -   [25] Spasojevicm, I.; Batinic-Haberle, I.; Inorg. Chim. Acta 2001,     317, 230-242. “Manganese (III) Complexes with Porphyrins and Related     Compounds as Catalytic Scavengers of Superoxide.” -   [26] Amaravathi, M.; Murthy, K. S. K.; Rao, M. K.; Reddy, B. S. Tet.     Lett. 2001, 42, 6745-6747. “Synthesis of     meso-Tetrakis(imidazol-5-yl) porphyrins.” -   [27] Milgrom, L. R.; Dempsey, P. J. F.; Yahioglu, G. Tet. Lett.     1996, 52, 9877-9890. “5,     10,15,20-Tetrakis(N-protected-imidazol-2-yl) porphyrins.” -   [28] Sanchez-Migallon, A.; de la Hoz, A.; Begtrup, M.;     Fernandez-Castano, C.; Foces-Foces, C.; Elguero, J. Tet. Lett. 1996,     10811-10822. “Porphyrins with Four Azole Substituents in meso     Positions. Part 2. X-ray Crystal Structure of meso-tetrkis     {1-[2-(trimethylsilyl)ethoxymethyl]pyrazol-5-yl}-porphyrin at 200K.” -   [29] Wohrle, D.; Gitzel, J.; Okura, I.; Aono, S. Photoredox     Properties of tetra-2,3-pyridinoporphyrazines     (29H,31H-tetrapyrido[2,3-b: 2′,3′-g: 2″,3″-l:     2″′,3″′-q]porphyrazine); J. Chem. Soc., Perkin Trans. 2 1985,     1171-8. -   [30] Weitner, T.; Budimir, A.; Kos, I.; Batinic-Haberle, I.;     Birus, M. J. Chem. Soc., Dalton Trans. 2010, 39, 11568-11576; c.     Budimir, A.; Smuc, T.; Weitner, T.; Batinic-Haberle, I.;     Birus, M. J. Coord. Chem. 2010, 63, 2750-2765. -   [31] Stuzhin, P. A.; Vagin, S. I.; Hanack, M. Synthesis and Spectral     Properties of Bisaxially Coordinated     (Octaphenyltetraazaporphyrinato)ruthenium(II) Complexes; Inorg.     Chem. 1998, 37, 2655-2662. -   [32] Fitzgerald, J. P.; Kaul, B. B.; Yee, G. T. Vanadium     [dicyanoperfluorostilbene]₂.yTHF: a molecule-based magnet with T_(C)     ≈205 K; Chem. Commun. 2000, 49-50. -   [33] Anderson, M. E.; Barrett, A. G. M.; Hoffman, B. M.     Super-Charged Porphyrazines: Synthesis and Physical Properties of     Octacationic Tetraazaporphyrins; Inorg. Chem. 1999, 38, 6143-51. -   [34] Reese, C. B.; Zhang, P. Z. Phosphotriester Approach to the     Synthesis of Oligonucleotides: A Reappraisal; J. Chem. Soc., Perkin     Trans. 1 1993, 2291-301. -   [35] C. Baird, M. C. Cann, Environmental Chemistry, 3rd ed., W.H.     Freeman and Co., New York, 2005. -   [36] Alternative Disinfectants and Oxidants Guidance Manual (EPA     815-R-99-014), 1999. -   [37] D. Fabian, G. Gordon, J. Inorg. Chem. 1992, 31, 2144. -   [38] P. T. Anastas, J. C. Warner, Green Chemistry: Theory and     Practice, Oxford University Press, 1998. -   [39] D. Lahaye, J. T. Groves, J. Inorg. Biochem. 2007, 101, 1786. -   [40] A. Q. Lee, B. R. Streit, M. J. Zdilla, M. M. Abu-Omar, J. L.     DuBois, Proc. Nat. Acad. Sci. USA 2008, 105, 15654. -   [41] R. G. Kieffer, G. Gordon, Inorg. Chem. 1968, 7, 239. -   [51] N. Jin, M. Ibrahim, T. G. Spiro, J. T. Groves, J. Am. Chem.     Soc. 2007, 129, 12416. -   [43] R. H. Holm, J. P. Donahue, Polyhedron 1993, 12, 571. -   [44] H. A. Laitinen, K. W. Boyer, Anal. Chem. 1972, 44, 920. -   [45] N. Jin, J. T. Groves, J. Am. Chem. Soc. 1999, 121, 2923. -   [46] J. T. Groves, J. B. Lee, S. S. Marla, J. Am. Chem. Soc. 1997,     119, 6269. -   [47] Sampling and Analytical Methods: Chlorine and Chlorine Dioxide     in Workplace Atmospheres (OSHA method 126SGX), United States     Department of Labor, 2008. -   [48] a)M. J. Zdilla, A. Q. Lee, M. M. Abu-Omar, Angew. Chem. Int.     Ed. 2008, 47, 7697; b)M. J. Zdilla, A. Q. Lee, M. M. Abu-Omar,     Inorg. Chem. 2009, 48, 2260. -   [49] L. M. Slaughter, J. P. Collman, T. A. Eberspacher, J. I.     Brauman, Inorg. Chem. 2004, 43, 5198. -   [50] S. Shahangian, L. P. Hager, J. Biol. Chem. 1981, 256, 6034. -   [51] C. Jakopitsch, H. Spalteholz, P. G. Furtmuller, J. Arnhold, C.     Obinger, J. Inorg. Biochem. 2008, 102, 293. -   [52] a)J. T. Groves, S. S. Marla, J. Am. Chem. Soc. 1995, 117, 9578;     b)S. S. Marla, J. Lee, J. T. Groves, Proc. Nat. Acad. Sci. USA 1997,     94, 14243. -   [53] N. Jin, J. L. Bourassa, S.C. Tizio, J. T. Groves, Angew. Chem.     Int. Ed. 2000, 39, 3849. -   [54] G. Peintler, I. Nagypal, I. R. Epstein, J. Phys. Chem. 1990,     94, 2954. -   [55] J. S, Nicoson, D. W. Margerum, Inorg. Chem. 2002, 41, 342. -   [56] H. A. Laitinen, K. W. Boyer, Anal. Chem. 1972, 44, 920. -   [57] Sampling and Analytical Methods: Chlorine and Chlorine Dioxide     in Workplace Atmospheres (OSHA method 126SGX), United States     Department of Labor, 2008.

The references cited throughout this application, are incorporated for all purposes apparent herein and in the references themselves as if each reference was fully set forth. For the sake of presentation, specific ones of these references may be cited at particular locations herein. A citation of a reference at a particular location indicates a manner(s) in which the teachings of the reference are incorporated. However, a citation of a reference at a particular location does not limit the manner in which all of the teachings of the cited reference are incorporated for all purposes.

It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but is intended to cover all modifications which are within the spirit and scope of the invention as defined by the appended claims; the drawings and/or the above description. 

What is claimed is:
 1. A method of generating chlorine dioxide comprising exposing ClO₂ ⁻ to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst.
 2. The method of claim 1, wherein the manganese porphyrin catalyst has a structure of formula I:

wherein the a is the oxidation state II, III or IV of the Mn and R₁, R₂, R₃, and R₄ are independently selected from the group consisting of TM2PyP, TM4PyP, TDMImP, and TDMBImp, which have a structure of formulas II, III, IV and V, respectively:

and at least one of R₅, R₆, R₇, R₈, R₉, and R₁₀ are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyl₁ is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(P)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 3. The method of claim 2, wherein R₁, R₂, R₃ and R₄ are TDMBImp.
 4. The method of claim 2, wherein R₁, R₂, R₃ and R₄ are TM2PyP or R₁, R₂, R₃ and R₄ are TM4PyP.
 5. The method of claim 1, wherein the manganese porphyrazine catalyst has a structure of formula VI:

wherein a is the oxidation state II, III or IV of the Mn and each of A₁, A₂, A₃, A₄, B₁, B₂, B₃, B₄, C₁, C₂, C₃, C₄, D₁, D₂, D₃ and D₄ are independently selected from N⁺—R_(n), C—H, C—X, and C—R_(n); when N⁺—R_(n) is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, and D₄ is when N is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, or D₄ is N; each R_(n) is independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 6. The method of claim 1, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of chlorite salts.
 7. The method of claim 1, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of sodium chlorite, potassium chlorite, calcium chlorite and magnesium chlorite.
 8. The method of claim 1, wherein the ClO₂ ⁻ is mixed with a solid filler.
 9. The method of claim 1, wherein the ClO₂ ⁻ is adsorbed on at least one substance selected from the group consisting of clay, silica, alumina and organic polymers.
 10. The method of claim 1, wherein at least one of the manganese porphyrin catalyst or a manganese porphyrazine catalyst is adsorbed on a solid support.
 11. The method of claim 10, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.
 12. A kit for generating chlorine dioxide comprising at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst and instructions to combine the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst with ClO₂ ⁻.
 13. The kit of claim 12, wherein the manganese porphyrin catalyst has a structure of formula I:

wherein a is the oxidation state II, III or IV of the Mn and R₁, R₂, R₃ and R₄ are independently selected from the group consisting of TM2PyP, TM4PyP, TDMImP, and TDMBImp, which have a structure of formulas II, III, IV and V, respectively:

and at least one of R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O⁻, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 14. The kit of claim 13, wherein R₁, R₂, R₃ and R₄ are TDMBImp.
 15. The kit of claim 13, wherein R₁, R₂, R₃ and R₄ are TM2PyP or R₁, R₂, R₃ and R₄ are TM4PyP.
 16. The kit of claim 12, wherein the manganese porphyrazine catalyst has a structure of formula VI:

wherein a is the oxidation state II, III or IV of the Mn and each of A₁, A₂, A₃, A₄, B₁, B₂, B₃, B₄, C₁, C₂, C₃, C₄, D₁, D₂, D₃ and D₄ are independently selected from N⁺—R_(n), C—H, C—X, and C—R_(n); when N⁺—R_(n) is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, and D₄ is N⁺—R_(n); when N is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, or D₄ is N; each R_(n) is independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 17. The kit of claim 12, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of chlorite salts.
 18. The kit of claim 12, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of sodium chlorite, potassium chlorite, calcium chlorite and magnesium chlorite.
 19. The kit of claim 12, wherein the ClO₂ ⁻ is mixed with a solid filler.
 20. The kit of claim 12, wherein the ClO₂ ⁻ is adsorbed on at least one substance selected from the group consisting of clay, silica, alumina and organic polymers.
 21. The kit of claim 12, wherein at least one of the manganese porphyrin catalyst or a manganese porphyrazine catalyst is adsorbed on a solid support.
 22. The kit of claim 21, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.
 23. A cartridge comprising a housing and at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst in the housing, wherein the cartridge is adapted to allow reactants to contact the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst.
 24. The cartridge of claim 23, wherein the manganese porphyrin catalyst has a structure of formula I:

wherein the a is the oxidation state II, III or IV of the Mn and R₁, R₂, R₃ and R₄ are independently selected from the group consisting of TM2PyP, TM4PyP, TDMImP, and TDMBImp, which have a structure of formulas II, III, IV and V, respectively:

and at least one of R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m0)H); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 25. The cartridge of claim 24, wherein R₁, R₂, R₃ and R₄ are TDMBImp.
 26. The cartridge of claim 24, wherein R₁, R₂, R₃ and R₄ are TM2PyP or R₁, R₂, R₃ and R₄ are TM4PyP.
 27. The cartridge of claim 23, wherein the manganese porphyrazine catalyst has a structure of formula VI:

wherein a is the oxidation state II, III or IV of the Mn and each of A₁, A₂, A₃, A₄, B₁, B₂, B₃, B₄, C₁, C₂, C₃, C₄, D₁, D₂, D₃ and D₄ are independently selected from N⁺—R_(n), C—H, C—X, and C—R_(n); when N⁺—R_(n) is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, and D₄ is N⁺−R_(n); when N is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, or D₄ is N; each R_(n) is independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂ CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂ CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂ CH₂C(O)O(CH₂CH₂O)m CH₂ CH₂O⁻, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 28. The cartridge of claim 23, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of chlorite salts.
 29. The cartridge of claim 23, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of sodium chlorite, potassium chlorite, calcium chlorite and magnesium chlorite.
 30. The cartridge of claim 23, wherein the ClO₂ ⁻ is mixed with a solid filler.
 31. The cartridge of claim 23, wherein the ClO₂ ⁻ is adsorbed on at least one substance selected from the group consisting of clay, silica, alumina and organic polymers.
 32. The cartridge of claim 23, wherein at least one of the manganese porphyrin catalyst or a manganese porphyrazine catalyst is adsorbed on a solid support.
 33. The cartridge of claim 32, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.
 34. The cartridge of claim 23, wherein the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst and the source are separated by an interface.
 35. The cartridge of claim 34, wherein the interface is a solid material configured to allow mixing of the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst upon mechanical disruption.
 36. The cartridge of claim 35, wherein the mechanical disruption includes breaking of the solid material.
 37. The cartridge of claim 35, wherein the mechanical disruption includes dissolution of the solid material.
 38. The cartridge of claim 23, wherein the housing includes a first compartment and a second compartment, and the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst is in the first compartment and the source is in the second compartment.
 39. The cartridge of claim 38, wherein at least one of the manganese porphyrin catalyst or the manganese porphyrazine catalyst is adsorbed on a solid support.
 40. The cartridge of claim 39, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene and organic polymers.
 41. A method of treating a substance comprising generating chlorine dioxide by exposing ClO₂ ⁻ to at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst and exposing the substance to the chlorine dioxide.
 42. The method of claim 41, wherein the manganese porphyrin catalyst has a structure of formula I:

wherein the a is the oxidation state II, III or IV of the Mn and R₁, R₂, R₃ and R₄ are independently selected from the group consisting of TM2PyP, TM4PyP, TDMImP, and TDMBImp, which have a structure of formulas II, III, IV and V, respectively:

and at least one of R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O⁻, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m0)H); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 43. The method of claim 42, wherein R_(n) is TDMBImp.
 44. The method of claim 42, wherein R_(n) is TM2PyP or R_(n) is TM4PyP.
 45. The method of claim 41, wherein the manganese porphyrazine catalyst has a structure of formula VI:

wherein a is the oxidation state II, III or IV of the Mn and each of A₁, A₂, A₃, A₄, B₁, B₂, B₃, B₄, C₁, C₂, C₃, C₄, D₁, D₂, D₃ and D₄ are independently selected from N⁺—R_(n), C—H, C—X, and C—R_(n); when N⁺—R_(n) is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, and D₄ is N⁺—R_(n); when N is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, or D₄ is N; each R_(n) is independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 46. The method of claim 41, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of chlorite salts.
 47. The method of claim 41, wherein the ClO₂ ⁻ is provided from at least one substance selected from the group consisting of sodium chlorite, potassium chlorite, calcium chlorite and magnesium chlorite.
 48. The method of claim 41, wherein the substance is selected from the group consisting of water, a cooling tower liquid, wood pulp and contaminated building material.
 49. The method of claim 41, wherein the ClO₂ ⁻ and the at least one of a manganese porphyrin catalyst or a manganese porphyrazine catalyst are contained in a cartridge and the step of generating includes providing conditions within the cartridge for catalyzing the reaction of ClO₂ ⁻ to chlorine dioxide.
 50. The method of claim 41, wherein the step of exposing the substance to the chlorine dioxide includes introducing the substance into the cartridge.
 51. A composition comprising a manganese porphyrazine compound having a structure of formula VI:

wherein a is the oxidation state II, III or IV of the Mn and each of A₁, A₂, A₃, A₄, B₁, B₂, B₃, B₄, C₁, C₂, C₃, C₄, D₁, D₂, D₃ and D₄ are independently selected from N⁺—R_(n), C—H, C—X, and C—R_(n); when N⁺—R_(n) is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, and D₄ is N⁺—R_(n); when N is selected, only one in each set of A₁, B₁, C₁, and D₁; A₂, B₂, C₂, and D₂; A₃, B₃, C₃, and D₃; or A₄, B₄, C₄, or D₄ is N; each R_(n) is independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyl₁ is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R₁₅ is alkyl, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₂OCH₃, (CH₂)_(n)—X, (CH₂)_(n)—Y, (CH₂)_(n)Ar—X, (CH₂)_(n)Ar—Y, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CO₂CH₂CH₃, (OCH₂CH₂)_(m)—X, (OCH₂CH₂)_(m)—Y, Y₂—X, or Y₂C(Z₁)₃; Z₁ is CH₂OCH₂(CH₂)_(n)X, CH₂OCH₂(CH₂)_(n)Y, or (CH₂)_(n)C(O)Y₂C(Z₂)₃; Z₂ is CH₂OCH₂CH₂C(O)Y₂C(Z₄)₃; Z₄ is CH₂OCH₂CH₂X or (CH₂)_(n)C(O)—Y₂—C(Z₅)₃; Z₅ is CH₂OCH₂CH₂C(O)Y₂C(Z₆)₃; Z₆ is CH₂OCH₂CH₂C(O)O(CH₂CH₂O)_(m)CH₂CH₂O⁻, (CH₂)_(n)OCH₂C(CH₂OH)₃, (CH₂)_(n)OCH₂CH(CH₂OH)₂, (CH)_(n)OCH₂C(CH₂OH)₂(CH₃), (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂OH)₃]₃, (CH₂)_(n)OCH₂C[CH₂OCH₂C(CH₂O[CH₂CH₂O]_(m)CH₂CH₂OX)₃, CH₂CONH—Y, CH₂CO—Y, or CH₂CO(CH₂)_(P)—Y; Y is OH, (O—CH₂CH₂)_(m)—W₁ or (CH₂CH₂)_(m)—W₂; W₁ is OH, or (O—(CH₂CH₂)_(m)OH); W₂ is OR₁₆ and R₁₆ is alkyl; and Y₂ is —(CH₂)_(n)O—, —(CH₂)_(n)NH—, —(CH)_(n)S—; CH₂CONH—, CH₂COO—, or CH₂CO(CH₂)_(p)—; and L₁ and L₂ are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H, or alcohol.
 52. A composition comprising a solid support and a compound having Formula I:

wherein the a is the oxidation state II, III, or IV of the Mn; L1 and L2 are independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H or an alochol; and R1, R2, R3 and R4 are TDMImp, which has a structure of formula IV:

where at least one of R7 or R8 are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; carboxymethyl; carboxyethyl; and carboxybenzyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; and Y is OH; and wherein the compound is absorbed on the solid support.
 53. The composition of claim 52, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.
 54. The composition of claim 52 further comprising an acetate buffer or a phosphate buffer.
 55. The composition of claim 52 further comprising an oxidant.
 56. The composition of claim 52 further comprising an aqueous solvent.
 57. The composition of claim 56, wherein the composition has a pH of 4.5-7.2.
 58. The composition of claim 56, wherein the composition has a pH of 1-6.
 59. The composition of claim 56, wherein the composition is acidic.
 60. The composition of claim 52 further comprising a chlorite salt.
 61. The composition of claim 52 further comprising a bromide salt.
 62. A composition comprising a compound having Formula I:

wherein the a is the oxidation state II, III, or IV of the Mn; L1 and L2 are independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H or an alochol; and R1, R2, R3 and R4 are TDMImp, which has a structure of formula IV:

where at least one of R7 or R8 are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; carboxymethyl; carboxyethyl; and carboxybenzyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; and Y is OH; and at least one of a buffer or an oxidant.
 63. The composition of claim 62 further comprising a solid support.
 64. The composition of claim 63, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.
 65. A composition comprising a compound having Formula I:

wherein the a is the oxidation state II, III, or IV of the Mn; L1 and L2 are independently absent, halide, oxo, aquo, hydroxo, CN, OPO₃H or an alochol; and R1, R2, R3 and R4 are TDMImp, which has a structure of formula IV:

where at least one of R7 or R8 are independently selected from the group consisting of H; methyl; ethyl; propyl; isopropyl; n-butyl; sec-butyl; isobutyl; carboxymethyl; carboxyethyl; and carboxybenzyl; CH₂—(CH₂)_(n1)—CH₃ where n1=5-20; CH₂—(CH₂)_(n2)—CH₂—X where n2=0-20; —CH₂(CO)—(CH₂)_(n3)—CH₂—X where n3=0-20; —CH₂—Ar—X; (CH₂)_(n)—X; (CH₂)_(m)Ar—X; (CH₂)_(m)Ar—Y; (CH₂)_(n)—Y; CH₂CONH—Y; CH₂COO—Y; CH₂CO(CH₂)_(P)—Y; (OCH₂CH₂)_(m)—Y; (OCH₂CH₂)_(m)—X; Y₂—X; CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃ and —CH₂CO₂CH₂CH₃; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH₂—Ar—X, (CH₂)_(m)Ar—X, or (CH₂)_(m)Ar—Y, the X or Y is attached ortho- meta- or para to the —CH₂— attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl₁), CONH₂, CONH(alkyl₁), CON(alkyl₁)₂, CO(CH₂)_(p)alkyl₁, OPO₃H₂, PO₃H₂, SO₃H, NH₂, N(alkyl₁)₂, or N(alkyl₁)₃ ⁺, where alkyls is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; and Y is OH; and at least one of a chlorite salt or a bromide salt.
 66. The composition of claim 65 further comprising sodium chloride.
 67. The composition of claim 65 further comprising a solid support.
 68. The composition of claim 67, wherein the solid support includes a substance selected from the group consisting of clay, silica, alumina, glass beads, functionalized polystyrene or organic polymers.
 69. The composition of claim 65 further comprising an acetate buffer or a phosphate buffer.
 70. The composition of claim 65 further comprising an aqueous solvent.
 71. The composition of claim 70, wherein the composition has a pH of 4.5-7.2.
 72. The composition of claim 70, wherein the composition has a pH of 1-6.
 73. The composition of claim 70, wherein the composition is acidic. 